fbpx
Wikipedia

Psilocybin

September 26, 2023

Psilocybin[a] (/ˌsaɪləˈsaɪbɪn/ sy-lə-SY-bin, /ˌsɪl-/) is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi. The most potent are members of genus Psilocybe, such as P. azurescens, P. semilanceata, and P. cyanescens, but psilocybin has also been isolated from about a dozen other genera. Psilocybin is itself biologically inactive but is quickly converted by the body to psilocin, which has mind-altering effects similar, in some aspects, to those of lysergic acid diethylamide (LSD), mescaline, and dimethyltryptamine (DMT). In general, the effects include euphoria, visual and mental hallucinations, changes in perception, distorted sense of time, and perceived spiritual experiences. It can also cause adverse reactions such as nausea and panic attacks.

Psilocybin
Names
Preferred IUPAC name
3-[2-(Dimethylamino)ethyl]-1H-indol-4-yl dihydrogen phosphate
Identifiers
  • 520-52-5 Y
3D model (JSmol)
  • Interactive image
273158
ChEBI
  • CHEBI:8614 Y
ChEMBL
  • ChEMBL194378 Y
ChemSpider
  • 10178 Y
ECHA InfoCard 100.007.542
EC Number
  • 208-294-4
KEGG
  • C07576 Y
MeSH Psilocybine
  • 10624
RTECS number
  • NM3150000
UNII
  • 2RV7212BP0 Y
  • DTXSID0048898
  • InChI=1S/C12H17N2O4P/c1-14(2)7-6-9-8-13-10-4-3-5-11(12(9)10)18-19(15,16)17/h3-5,8,13H,6-7H2,1-2H3,(H2,15,16,17) Y
    Key: QVDSEJDULKLHCG-UHFFFAOYSA-N Y
  • InChI=1/C12H17N2O4P/c1-14(2)7-6-9-8-13-10-4-3-5-11(12(9)10)18-19(15,16)17/h3-5,8,13H,6-7H2,1-2H3,(H2,15,16,17)
  • CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O
Pharmacology
Low
Oral, intravenous
Pharmacokinetics:
Hepatic
Oral: 163±64 min
Intravenous: 74.1±19.6 min[1]
Renal
Legal status
Properties
C12H17N2O4P
Molar mass 284.252 g·mol−1
Melting point 220–228 °C (428–442 °F)[3]
Soluble
Solubility Soluble in boiling methanol and water
slightly soluble in ethanol
insoluble in chloroform, benzene[4]
Hazards
Lethal dose or concentration (LD, LC):
285 mg/kg (mouse, i.v.)
280 mg/kg (rat, i.v.)
12.5 mg/kg (rabbit, i.v.)[3]
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Y verify (what is YN ?)

Imagery found on cave paintings and rock art of modern-day Spain and Algeria suggests that human use of psilocybin mushrooms predates recorded history[citation needed]. In Mesoamerica, the mushrooms had long been consumed in spiritual and divinatory ceremonies before Spanish chroniclers first documented their use in the sixteenth century. In 1958, the Swiss chemist Albert Hofmann isolated psilocybin and psilocin from the mushroom Psilocybe mexicana. Hofmann's employer Sandoz marketed and sold pure psilocybin to physicians and clinicians worldwide for use in psychedelic therapy. Although the increasingly restrictive drug laws of the 1960s and the 1970s curbed scientific research into the effects of psilocybin and other hallucinogens, its popularity as an entheogen (spirituality-enhancing agent) grew in the next decade, owing largely to the increased availability of information on how to cultivate psilocybin mushrooms.

The intensity and duration of the effects of psilocybin are variable, depending on species or cultivar of mushrooms, dosage, individual physiology, and set and setting, as was shown in experiments led by Timothy Leary at Harvard University in the early 1960s. Once ingested, psilocybin is rapidly metabolized to psilocin, which then acts on serotonin receptors in the brain. The mind-altering effects of psilocybin typically last from two to six hours, although to individuals under the influence of psilocybin, the effects may seem to last much longer, since the drug can distort the perception of time. Possession of psilocybin-containing mushrooms has been outlawed in most countries, and psilocybin has been classified as a Schedule I controlled substance under the 1971 United Nations Convention on Psychotropic Substances.

Effects Edit

 
American psychologist and counterculture figure Timothy Leary conducted early experiments into the effects of psychedelic drugs, including psilocybin (1989 photo)

The effects of psilocybin are highly variable and depend on the mindset and environment in which the user has the experience, factors commonly referred to as set and setting. In the early 1960s, Timothy Leary and colleagues at Harvard University investigated the role of set and setting on the effects of psilocybin. They administered the drug to 175 volunteers from various backgrounds in an environment intended to be similar to a comfortable living room. 98 of the subjects were given questionnaires to assess their experiences and the contribution of background and situational factors. Individuals who had experience with psilocybin prior to the study reported more pleasant experiences than those for whom the drug was novel. Group size, dosage, preparation, and expectancy were important determinants of the drug response. In general, those in groups of more than eight felt that the groups were less supportive, and their experiences less pleasant. Conversely, smaller groups (fewer than six) were seen as more supportive and reported more positive reactions to the drug in those groups. Leary and colleagues proposed that psilocybin heightens suggestibility, making an individual more receptive to interpersonal interactions and environmental stimuli.[6] These findings were affirmed in a later review by Jos ten Berge (1999), who concluded that dosage, set, and setting were fundamental factors in determining the outcome of experiments that tested the effects of psychedelic drugs on artists' creativity.[7]

After ingesting psilocybin, a wide range of subjective effects may be experienced: feelings of disorientation, lethargy, giddiness, euphoria, joy, and depression. In one study, 31% of volunteers given a high dose reported feelings of significant fear and 17% experienced transient paranoia.[8] In studies at Johns Hopkins among those given a moderate dose (but still enough to "give a high probability of a profound and beneficial experience"), negative experiences were rare, whereas one-third of those given a high dose experienced anxiety or paranoia.[9][10] Low doses can induce hallucinatory effects. Closed-eye hallucinations may occur, where the affected individual sees multicolored geometric shapes and vivid imaginative sequences.[11] Some individuals report synesthesia, such as tactile sensations when viewing colors.[12]: 175  At higher doses, psilocybin can lead to "intensification of affective responses, enhanced ability for introspection, regression to primitive and childlike thinking, and activation of vivid memory traces with pronounced emotional undertones".[13] Open-eye visual hallucinations are common, and may be very detailed although rarely confused with reality.[11]

A 2011 prospective study by Roland R. Griffiths and colleagues suggests that a single high dosage of psilocybin can cause long-term changes in the personality of its users. About half of the study participants—described as healthy, "spiritually active", and many possessing postgraduate degrees—showed an increase in the personality dimension of openness (assessed using the Revised NEO Personality Inventory), and this positive effect was apparent more than a year after the psilocybin session. According to the study authors, the finding is significant because "no study has prospectively demonstrated personality change in healthy adults after an experimentally manipulated discrete event".[14] A further study by Griffiths in 2017 found that doses of 20 to 30mg/70kg psilocybin inducing mystical-type experiences brought more lasting changes to traits including altruism, gratitude, forgiveness and feeling close to others when they were combined with a regular meditation practice and an extensive spiritual practice support program.[15][16] Although other researchers have described instances of psychedelic drug usage leading to new psychological understandings and personal insights,[17] it is not known whether these experimental results can be generalized to larger populations.[14]

Physical effects Edit

Common responses include pupil dilation (93%); changes in heart rate (100%), including increases (56%), decreases (13%), and variable responses (31%); changes in blood pressure (84%), including hypotension (34%), hypertension (28%), and general instability (22%); changes in stretch reflex (86%), including increases (80%) and decreases (6%); nausea (44%); tremor (25%); and dysmetria (16%) (inability to properly direct or limit motions).[b] The temporary increases in blood pressure caused by the drug can be a risk factor for users with pre-existing hypertension.[11] These qualitative somatic effects caused by psilocybin have been corroborated by several early clinical studies.[19] A 2005 magazine survey of clubgoers in the UK found that nausea or vomiting was experienced by over a quarter of those who had used psilocybin mushrooms in the last year, although this effect is caused by the mushroom rather than psilocybin itself.[8] In one study, administration of gradually increasing dosages of psilocybin daily for 21 days had no measurable effect on electrolyte levels, blood sugar levels, or liver toxicity tests.[1]

Perceptual distortions Edit

 
The ability of psilocybin to cause perceptual distortions is linked to its influence on the activity of the prefrontal cortex

Psilocybin is known to strongly influence the subjective experience of the passage of time.[20] Users often feel as if time is slowed down, resulting in the perception that "minutes appear to be hours" or "time is standing still".[21] Studies have demonstrated that psilocybin significantly impairs subjects' ability to gauge time intervals longer than 2.5 seconds, impairs their ability to synchronize to inter-beat intervals longer than 2 seconds, and reduces their preferred tapping rate.[21][22] These results are consistent with the drug's role in affecting prefrontal cortex activity,[23] and the role that the prefrontal cortex is known to play in time perception.[24] However, the neurochemical basis of psilocybin's effects on the perception of time are not known with certainty.[25]

Users having a pleasant experience can feel a sense of connection to others, nature, and the universe; other perceptions and emotions are also often intensified. Users having an unpleasant experience (a "bad trip") describe a reaction accompanied by fear, other unpleasant feelings, and occasionally by dangerous behavior. In general, the phrase "bad trip" is used to describe a reaction that is characterized primarily by fear or other unpleasant emotions, not just transitory experience of such feelings. A variety of factors may contribute to a psilocybin user experiencing a bad trip, including "tripping" during an emotional or physical low or in a non-supportive environment (see: set and setting). Ingesting psilocybin in combination with other drugs, including alcohol, can also increase the likelihood of a bad trip.[8][26] Other than the duration of the experience, the effects of psilocybin are similar to comparable dosages of lysergic acid diethylamide (LSD) or mescaline. However, in the Psychedelics Encyclopedia, author Peter Stafford noted, "The psilocybin experience seems to be warmer, not as forceful and less isolating. It tends to build connections between people, who are generally much more in communication than when they use LSD."[27]: 273 

Group perceptions Edit

Through further anthropological studies regarding "personal insights"[28] and the psycho-social effects of psilocybin, it can be seen in many traditional societies that powerful mind-active substances such as psilocybin are regularly "consumed ritually for therapeutic purposes or for transcending normal, everyday reality".[29] Positive effects that psilocybin has on individuals can be observed by taking on an anthropological approach and moving away from the Western bio-medical society; this is aided by the studies done by Leary.[30] Within certain traditional societies where the use of psilocybin is frequent for shamanic healing rituals, group collectives praise their guide, healer and shaman for helping alleviate them of pains, aches and hurt. They do this through a group ritual practice where participants, or just the guide, ingests psilocybin to help extract any "toxic psychic residues or sorcerous implants"[29] found in one's body. Group therapies using classic psychedelics are becoming more commonly used in the Western world in clinical practice. This may continue to grow as long providing the evidence remains indicative of safety and efficacy.[31] In social sense, the group is shaped by their experiences surrounding psilocybin and how they view the plant collectively. As mentioned in the anthropology article,[29] the group partakes in a "journey" together, thus adding to the spiritual, social body, where roles, hierarchies and gender are subjectively understood.[29]

Mystical experiences Edit

 
In their studies on the psilocybin experience, Johns Hopkins researchers use peaceful music and a comfortable room to help ensure a comfortable setting, and experienced guides to monitor and reassure the volunteers

Psilocybin mushrooms have been and continue to be used in indigenous New World cultures in religious, divinatory, or spiritual contexts. Reflecting the meaning of the word entheogen ("the god within"), the mushrooms are revered as powerful spiritual sacraments that provide access to sacred worlds. Typically used in small group community settings, they enhance group cohesion and reaffirm traditional values.[32] Terence McKenna documented the worldwide practices of psilocybin mushroom usage as part of a cultural ethos relating to the Earth and mysteries of nature, and suggested that mushrooms enhanced self-awareness and a sense of contact with a "Transcendent Other"—reflecting a deeper understanding of our connectedness with nature.[33]

Psychedelic drugs can induce states of consciousness that have lasting personal meaning and spiritual significance in individuals who are religious or spiritually inclined; these states are called mystical experiences. Some scholars have proposed that many of the qualities of a drug-induced mystical experience are indistinguishable from mystical experiences achieved through non-drug techniques, such as meditation or holotropic breathwork.[34][35] In the 1960s, Walter Pahnke and colleagues systematically evaluated mystical experiences (which they called "mystical consciousness") by categorizing their common features. These categories, according to Pahnke, "describe the core of a universal psychological experience, free from culturally determined philosophical or theological interpretations", and allow researchers to assess mystical experiences on a qualitative, numerical scale.[36]

In the 1962 Marsh Chapel Experiment, which was run by Pahnke at the Harvard Divinity School under the supervision of Timothy Leary,[37] almost all of the graduate degree divinity student volunteers who received psilocybin reported profound religious experiences.[38] One of the participants was religious scholar Huston Smith, author of several textbooks on comparative religion; he later described his experience as "the most powerful cosmic homecoming I have ever experienced."[39] In a 25-year followup to the experiment, all of the subjects given psilocybin described their experience as having elements of "a genuine mystical nature and characterized it as one of the high points of their spiritual life".[40]: 13  Psychedelic researcher Rick Doblin considered the study partially flawed due to incorrect implementation of the double-blind procedure, and several imprecise questions in the mystical experience questionnaire. Nevertheless, he said that the study cast "a considerable doubt on the assertion that mystical experiences catalyzed by drugs are in any way inferior to non-drug mystical experiences in both their immediate content and long-term effects".[40]: 24  This sentiment was echoed by psychiatrist William A. Richards, who in a 2007 review stated "[psychedelic] mushroom use may constitute one technology for evoking revelatory experiences that are similar, if not identical, to those that occur through so-called spontaneous alterations of brain chemistry."[41]

A group of researchers from Johns Hopkins School of Medicine led by Roland Griffiths conducted a study to assess the immediate and long-term psychological effects of the psilocybin experience, using a modified version of the mystical experience questionnaire and a rigorous double-blind procedure.[42] When asked in an interview about the similarity of his work with Leary's, Griffiths explained the difference: "We are conducting rigorous, systematic research with psilocybin under carefully monitored conditions, a route which Dr. Leary abandoned in the early 1960s."[43] The National Institute of Drug Abuse-funded study, published in 2006, has been praised by experts for the soundness of its experimental design.[c] In the experiment, 36 volunteers without prior experience with hallucinogens were given psilocybin and methylphenidate (Ritalin) in separate sessions; the methylphenidate sessions served as a control and psychoactive placebo. The degree of mystical experience was measured using a questionnaire developed by Ralph W. Hood;[44] 61% of subjects reported a "complete mystical experience" after their psilocybin session, while only 13% reported such an outcome after their experience with methylphenidate. Two months after taking psilocybin, 79% of the participants reported moderately to greatly increased life satisfaction and sense of well-being. About 36% of participants also had a strong to extreme "experience of fear" or dysphoria (i.e., a "bad trip") at some point during the psilocybin session (which was not reported by any subject during the methylphenidate session); about one-third of these (13% of the total) reported that this dysphoria dominated the entire session. These negative effects were reported to be easily managed by the researchers and did not have a lasting negative effect on the subject's sense of well-being.[45]

A follow-up study conducted 14 months after the original psilocybin session confirmed that participants continued to attribute deep personal meaning to the experience. Almost one-third of the subjects reported that the experience was the single most meaningful or spiritually significant event of their lives, and over two-thirds reported it among their five most spiritually significant events. About two-thirds indicated that the experience increased their sense of well-being or life satisfaction.[38] Even after 14 months, those who reported mystical experiences scored on average 4 percentage points higher on the personality trait of Openness/Intellect; personality traits are normally stable across the lifespan for adults. Likewise, in a recent (2010) web-based questionnaire study designed to investigate user perceptions of the benefits and harms of hallucinogenic drug use, 60% of the 503 psilocybin users reported that their use of psilocybin had a long-term positive impact on their sense of well-being.[8][46]

While many recent studies have concluded that psilocybin can cause mystical-type experiences having substantial and sustained personal meaning and spiritual significance, not all the medical community agree. Paul R. McHugh, formerly director of the Department of Psychiatry and Behavioral Science at Johns Hopkins, responded as follows in a book review: "The unmentioned fact in The Harvard Psychedelic Club is that LSD, psilocybin, mescaline, and the like produce not a "higher consciousness" but rather a particular kind of "lower consciousness" known well to psychiatrists and neurologists—namely, 'toxic delirium.'"[47]

Available forms Edit

Although psilocybin may be prepared synthetically, outside of the research setting it is not typically used in this form. The psilocybin present in certain species of mushrooms can be ingested in several ways: by consuming fresh or dried fruit bodies, by preparing an herbal tea, or by combining with other foods to mask the bitter taste.[48] In rare cases people have injected mushroom extracts intravenously.[8]

Adverse effects Edit

Most of the comparatively few fatal incidents reported in the literature that are associated with psychedelic mushroom usage involve the simultaneous use of other drugs, especially alcohol. Probably the most common cause of hospital admissions resulting from psychedelic mushroom usage involves "bad trips" or panic reactions, in which affected individuals become extremely anxious, confused, agitated, or disoriented. Accidents, self-injury, or suicide attempts can result from serious cases of acute psychotic episodes.[8] Although no studies have linked psilocybin with birth defects,[49] it is recommended that pregnant women avoid its usage.[50]

Toxicity Edit

Data are sparse, but in the decade leading up to 2020, an increasing number of psilocybin mushroom overdoses were recorded. Nonetheless, the number of events requiring hospitalization remain rare, and overdoses are generally mild and self-limiting. A review regarding the management of psychedelic overdoses suggested that psilocybin related overdose management should prioritize managing the immediate adverse effects, such as anxiety and paranoia, rather than specific pharmacological interventions, as its physiological toxicity tends to be rather limited.[51] One analysis of mushrooms used by people hospitalized from psilocybin poisoning found high concentrations of phenethylamine (PEA), which has also been detected in the urine of people who have used psilocybin mushrooms. It is hypothesized that PEA may intensify the effect of psilocybin poisoning.[51]

In rats, the median lethal dose (LD50) when administered orally is 280 milligrams per kilogram (mg/kg), approximately one and a half times that of caffeine. When administered intravenously in rabbits, psilocybin's LD50 is approximately 12.5 mg/kg.[52] Psilocybin comprises approximately 1% of the weight of Psilocybe cubensis mushrooms, and so nearly 1.7 kilograms (3.7 lb) of dried mushrooms, or 17 kilograms (37 lb) of fresh mushrooms, would be required for a 60-kilogram (130 lb) person to reach the 280 mg/kg LD50 value of rats.[8] Based on the results of animal studies, the lethal dose of psilocybin has been extrapolated to be 6 grams, 1000 times greater than the effective dose of 6 milligrams.[53] The Registry of Toxic Effects of Chemical Substances assigns psilocybin a relatively high therapeutic index of 641 (higher values correspond to a better safety profile); for comparison, the therapeutic indices of aspirin and nicotine are 199 and 21, respectively.[54] The lethal dose from psilocybin toxicity alone is unknown, and has rarely been documented—as of 2011, only two cases attributed to overdosing on hallucinogenic mushrooms (without concurrent use of other drugs) have been reported in the scientific literature and may involve other factors aside from psilocybin.[8][d]

Psychiatric Edit

Panic reactions can occur after consumption of psilocybin-containing mushrooms, especially if the ingestion is accidental or otherwise unexpected. Reactions characterized by violent behavior, suicidal thoughts,[57] schizophrenia-like psychosis,[58][59] and convulsions[60] have been reported in the literature. A 2005 survey conducted in the United Kingdom found that almost a quarter of those who had used psilocybin mushrooms in the past year had experienced a panic attack.[8][failed verification] Other adverse effects less frequently reported include paranoia, confusion, prolonged derealization (disconnection from reality), and mania.[46] Psilocybin usage can temporarily induce a state of depersonalization disorder.[61] Usage by those with schizophrenia can induce acute psychotic states requiring hospitalization.[62]

The similarity of psilocybin-induced symptoms to those of schizophrenia has made the drug a useful research tool in behavioral and neuroimaging studies of this psychotic disorder.[63][64][65] In both cases, psychotic symptoms are thought to arise from a "deficient gating of sensory and cognitive information" in the brain that ultimately lead to "cognitive fragmentation and psychosis".[64] Flashbacks (spontaneous recurrences of a previous psilocybin experience) can occur long after having used psilocybin mushrooms. Hallucinogen persisting perception disorder (HPPD) is characterized by a continual presence of visual disturbances similar to those generated by psychedelic substances. Neither flashbacks nor HPPD are commonly associated with psilocybin usage,[8] and correlations between HPPD and psychedelics are further obscured by polydrug use and other variables.[66]

Tolerance and dependence Edit

 
Chart of dependence potential and effective dose/lethal dose ratio of several psychoactive drugs[67]

Tolerance to psilocybin builds and dissipates quickly; ingesting psilocybin more than about once a week can lead to diminished effects. Tolerance dissipates after a few days, so doses can be spaced several days apart to avoid the effect.[68] A cross-tolerance can develop between psilocybin and the pharmacologically similar LSD,[69] and between psilocybin and phenethylamines such as mescaline and DOM.[70]

Repeated use of psilocybin does not lead to physical dependence.[1] A 2008 study concluded that, based on US data from the period 2000–2002, adolescent-onset (defined here as ages 11–17) usage of hallucinogenic drugs (including psilocybin) did not increase the risk of drug dependence in adulthood; this was in contrast to adolescent usage of cannabis, cocaine, inhalants, anxiolytic medicines, and stimulants, all of which were associated with "an excess risk of developing clinical features associated with drug dependence".[71] Likewise, a 2010 Dutch study ranked the relative harm of psilocybin mushrooms compared to a selection of 19 recreational drugs, including alcohol, cannabis, cocaine, ecstasy, heroin, and tobacco. Psilocybin mushrooms were ranked as the illicit drug with the lowest harm,[72] corroborating conclusions reached earlier by expert groups in the United Kingdom.[73]

Chemistry Edit

Physical properties Edit

Psilocybin is a naturally-occurring substituted tryptamine that features an indole ring linked to an aminoethyl substituent. It is structurally related to serotonin, a monoamine neurotransmitter which is a derivative of the amino acid tryptophan. Psilocybin is a member of the general class of tryptophan-based compounds that originally functioned as antioxidants in earlier life forms before assuming more complex functions in multicellular organisms, including humans.[74] Other related indole-containing psychedelic compounds include dimethyltryptamine, found in many plant species and in trace amounts in some mammals, and bufotenin, found in the skin of certain amphibians, especially the Colorado River toad.[75]: 10–13 

Psilocybin is a white, crystalline solid that is soluble in water, methanol and ethanol but insoluble in nonpolar organic solvents such as chloroform and petroleum ether.[75]: 15  It has a melting point between 220–228 °C (428–442 °F),[52] and an ammonia-like taste.[76] Its pKa values are estimated to be 1.3 and 6.5 for the two successive phosphate hydroxy groups and 10.4 for the dimethylamine nitrogen, so it typically exists as a zwitterionic structure.[76] There are two known crystalline polymorphs of psilocybin, as well as reported hydrated phases.[77] Psilocybin rapidly oxidizes upon exposure to light—an important consideration when using it as an analytical standard.[78]

Laboratory synthesis Edit

Albert Hofmann et al. were the first team to synthesize psilocybin in 1958. Since that time, various chemists have improved the methods for the laboratory synthesis and purification of psilocybin. In particular, Shirota et al. reported a novel method in 2003 for the synthesis of psilocybin at the gram scale from 4-hydroxyindole that does not require chromatographic purification. Fricke et al. described an enzymatic pathway for the synthesis of psilocybin and psilocin, publishing their results in 2017. Sherwood et al. significantly improved upon Shirota's method (producing at the kilogram scale while employing less expensive reagents), publishing their results in 2020.[79]

Biosynthesis Edit

 
Biosynthetic route previously thought to lead to psilocybin. It has recently been shown that 4-hydroxylation and O-phosphorylation immediately follow decarboxylation, and neither dimethyltryptamine nor psilocin are intermediates, although spontaneously generated psilocin can be converted back to psilocybin.[80]

Isotopic labeling experiments from the 1960s suggested that the biosynthesis of psilocybin was a four-step process:[81]

  1. decarboxylation of tryptophan to tryptamine
  2. N,N-dimethylation of tryptamine at the N9 position to dimethyltryptamine
  3. 4-hydroxylation of dimethyltryptamine to psilocin
  4. O-phosphorylation of psilocin to psilocybin

More recent research has demonstrated that—at least in P. cubensis—O-phosphorylation is in fact the third step, and that neither dimethyltryptamine nor psilocin are intermediates.[80] The sequence of the intermediate steps has been shown to involve four enzymes (PsiD, PsiH, PsiK, and PsiM) in P. cubensis and P. cyanescens, although it is possible that the biosynthetic pathway differs between species.[75]: 12–13 [80] These enzymes are encoded in gene clusters in Psilocybe, Panaeolus, and Gymnopilus.[82]

Escherichia coli has been genetically modified to manufacture large amounts of psilocybin.[83] Psilocybin can be produced de novo in GM yeast.[84][85]

Pharmacology Edit

Pharmacodynamics Edit

 
The neurotransmitter serotonin is structurally similar to psilocybin

Psilocybin is a psychoplastogen,[86][87][88] which refers to a compound capable of promoting rapid and sustained neuroplasticity.

Psilocybin is rapidly dephosphorylated in the body to psilocin, which is an agonist for several serotonin receptors, which are also known as 5-hydroxytryptamine (5-HT) receptors. In rats, psilocin binds with high affinity to 5-HT2A receptors and low affinity to 5-HT1 receptors, including 5-HT1A and 5-HT1D; effects are also mediated via 5-HT2C receptors.[1] The psychotomimetic (psychosis-mimicking) effects of psilocin can be blocked in a dose-dependent fashion by the 5-HT2A antagonist drug ketanserin.[58] Various lines of evidence have shown that interactions with non-5-HT2 receptors also contribute to the subjective and behavioral effects of the drug.[70][e] For example, psilocin indirectly increases the concentration of the neurotransmitter dopamine in the basal ganglia, and some psychotomimetic symptoms of psilocin are reduced by haloperidol, a non-selective dopamine receptor antagonist. Taken together, these suggest that there may be an indirect dopaminergic contribution to psilocin's psychotomimetic effects.[25] Psilocybin and psilocin have no affinity for dopamine receptor D2, unlike another common 5-HT receptor agonist, lysergic acid diethylamide (LSD).[1] Psilocin antagonizes H1 receptors with moderate affinity, compared to LSD which has a lower affinity.[90] Serotonin receptors are located in numerous parts of the brain, including the cerebral cortex, and are involved in a wide range of functions, including regulation of mood, motivation, body temperature, appetite and libido.[91]

Psilocybin induces region-dependent alterations in glutamate that may be associated with subjective experiences of ego dissolution.[92]

Pharmacokinetics Edit

 
Psilocybin is converted in the liver to the pharmacologically active psilocin, which is then either glucuronated to be excreted in the urine or further converted to various psilocin metabolites

The effects of the drug begin 10–40 minutes after ingestion, and last 2–6 hours depending on dose, species, and individual metabolism.[93]: 36–41  The half life of psilocybin is 163 ± 64 minutes when taken orally, or 74.1 ± 19.6 minutes when injected intravenously.[1]

Psilocybin is metabolized mostly in the liver. As it becomes converted to psilocin, it undergoes a first-pass effect, whereby its concentration is greatly reduced before it reaches the systemic circulation. Psilocin is broken down by the enzyme monoamine oxidase to produce several metabolites that can circulate in the blood plasma, including 4-hydroxyindole-3-acetaldehyde, 4-hydroxytryptophol, and 4-hydroxyindole-3-acetic acid.[1] Some psilocin is not broken down by enzymes and instead forms a glucuronide; this is a biochemical mechanism animals use to eliminate toxic substances by linking them with glucuronic acid, which can then be excreted in the urine.[94][95] Psilocin is glucuronated by the glucuronosyltransferase enzymes UGT1A9 in the liver, and by UGT1A10 in the small intestine.[96] Based on studies using animals, about 50% of ingested psilocybin is absorbed through the stomach and intestine. Within 24 hours, about 65% of the absorbed psilocybin is excreted into the urine, and a further 15–20% is excreted in the bile and feces. Although most of the remaining drug is eliminated in this way within 8 hours, it is still detectable in the urine after 7 days.[97] Clinical studies show that psilocin concentrations in the plasma of adults average about 8 μg/liter within 2 hours after ingestion of a single 15 mg oral psilocybin dose;[98] psychological effects occur with a blood plasma concentration of 4–6 μg/liter.[1] Psilocybin is approximately 1/100 the potency of LSD on a weight per weight basis, and the physiological effects last about half as long.[12]: 171 

Monoamine oxidase inhibitors (MAOI) have been known to prolong and enhance the effects of DMT and one study assumed that the effect on psilocybin would be similar since it is a structural analogue of DMT.[99] Alcohol consumption may enhance the effects of psilocybin, because acetaldehyde, one of the primary breakdown metabolites of consumed alcohol, reacts with biogenic amines present in the body to produce MAOIs related to tetrahydroisoquinoline and β-carboline.[8] Tobacco smokers may also experience more powerful effects with psilocybin,[8] because tobacco smoke exposure decreases the activity of MAO in the brain and peripheral organs.[100]

Analytical methods Edit

Several relatively simple chemical tests—commercially available as reagent testing kits—can be used to assess the presence of psilocybin in extracts prepared from mushrooms. The drug reacts in the Marquis test to produce a yellow color, and a green color in the Mandelin reagent.[101] Neither of these tests, however, is specific for psilocybin; for example, the Marquis test will react with many classes of controlled drugs, such as those containing primary amino groups and unsubstituted benzene rings, including amphetamine and methamphetamine.[102] Ehrlich's reagent and DMACA reagent are used as chemical sprays to detect the drug after thin layer chromatography.[103] Many modern techniques of analytical chemistry have been used to quantify psilocybin levels in mushroom samples. Although the earliest methods commonly used gas chromatography, the high temperature required to vaporize the psilocybin sample prior to analysis causes it to spontaneously lose its phosphoryl group and become psilocin—making it difficult to chemically discriminate between the two drugs. In forensic toxicology, techniques involving gas chromatography coupled to mass spectrometry (GC–MS) are the most widely used due to their high sensitivity and ability to separate compounds in complex biological mixtures.[104] These techniques include ion mobility spectrometry,[105] capillary zone electrophoresis,[106] ultraviolet spectroscopy,[107] and infrared spectroscopy.[108] High-performance liquid chromatography (HPLC) is used with ultraviolet,[78] fluorescence,[109] electrochemical,[110] and electrospray mass spectrometric detection methods.[111]

Various chromatographic methods have been developed to detect psilocin in body fluids: the rapid emergency drug identification system (REMEDi HS), a drug screening method based on HPLC;[112] HPLC with electrochemical detection;[110][113] GC–MS;[94][112] and liquid chromatography coupled to mass spectrometry.[114] Although the determination of psilocin levels in urine can be performed without sample clean-up (i.e., removing potential contaminants that make it difficult to accurately assess concentration), the analysis in plasma or serum requires a preliminary extraction, followed by derivatization of the extracts in the case of GC–MS. A specific immunoassay has also been developed to detect psilocin in whole blood samples.[115] A 2009 publication reported using HPLC to quickly separate forensically important illicit drugs including psilocybin and psilocin, which were identifiable within about half a minute of analysis time.[116] These analytical techniques to determine psilocybin concentrations in body fluids are, however, not routinely available, and not typically used in clinical settings.[26]

Natural occurrence Edit

Maximum reported psilocybin concentrations (% dry weight) in 12 Psilocybe species[93]: 39 
Species % psilocybin
P. azurescens 1.78
P. serbica 1.34
P. semilanceata 0.98
P. baeocystis 0.85
P. cyanescens 0.85
P. tampanensis 0.68
P. cubensis 0.63
P. weilii 0.61
P. hoogshagenii 0.60
P. stuntzii 0.36
P. cyanofibrillosa 0.21
P. liniformans 0.16

Psilocybin is present in varying concentrations in over 200 species of Basidiomycota mushrooms. In a 2000 review on the worldwide distribution of hallucinogenic mushrooms, Gastón Guzmán and colleagues considered these to be distributed amongst the following genera: Psilocybe (116 species), Gymnopilus (14), Panaeolus (13), Copelandia (12), Hypholoma (6), Pluteus (6), Inocybe (6), Conocybe (4), Panaeolina (4), Gerronema (2), and Galerina (1 species).[117] Guzmán increased his estimate of the number of psilocybin-containing Psilocybe to 144 species in a 2005 review. The majority of these are found in Mexico (53 species), with the remainder distributed in the United States and Canada (22), Europe (16), Asia (15), Africa (4), and Australia and associated islands (19).[118] The diversity of psilocybin mushrooms is reported to have been increased by horizontal transfer of the psilocybin gene cluster between unrelated mushroom species.[119][82] In general, psilocybin-containing species are dark-spored, gilled mushrooms that grow in meadows and woods of the subtropics and tropics, usually in soils rich in humus and plant debris.[75]: 5  Psilocybin mushrooms occur on all continents, but the majority of species are found in subtropical humid forests.[117] Psilocybe species commonly found in the tropics include P. cubensis and P. subcubensis. P. semilanceata—considered by Guzmán to be the world's most widely distributed psilocybin mushroom[120]—is found in Europe, North America, Asia, South America, Australia and New Zealand, but is entirely absent from Mexico.[118] Although the presence or absence of psilocybin is not of much use as a chemotaxonomical marker at the familial level or higher, it is used to classify taxa of lower taxonomic groups.[121]

 
Global distribution of over 100 psychoactive species of genus Psilocybe mushrooms.[122]
 
Psilocybin was first isolated from Psilocybe mexicana.
 
P. semilanceata is common in Europe, Canada, and the United States.

Both the caps and the stems contain psychoactive compounds, although the caps consistently contain more. The spores of these mushrooms do not contain psilocybin or psilocin.[105][123][124] The total potency varies greatly between species and even between specimens of a species collected or grown from the same strain.[125] Because most psilocybin biosynthesis occurs early in the formation of fruit bodies or sclerotia, younger, smaller mushrooms tend to have a higher concentration of the drug than larger, mature mushrooms.[126] In general, the psilocybin content of mushrooms is quite variable (ranging from almost nothing to 2.5% of the dry weight)[127][27]: 248  and depends on species, strain, growth and drying conditions, and mushroom size.[93]: 36–41, 52  Cultivated mushrooms have less variability in psilocybin content than wild mushrooms.[128] The drug is more stable in dried than fresh mushrooms; dried mushrooms retain their potency for months or even years,[93]: 51–5  while mushrooms stored fresh for four weeks contain only traces of the original psilocybin.[8]

The psilocybin contents of dried herbarium specimens of Psilocybe semilanceata in one study were shown to decrease with the increasing age of the sample: collections dated 11, 33, or 118 years old contained 0.84%, 0.67%, and 0.014% (all dry weight), respectively.[129] Mature mycelia contain some psilocybin, while young mycelia (recently germinated from spores) lack appreciable amounts.[130] Many species of mushrooms containing psilocybin also contain lesser amounts of the analog compounds baeocystin and norbaeocystin,[93]: 38  chemicals thought to be biogenic precursors.[12]: 170  Although most species of psilocybin-containing mushrooms bruise blue when handled or damaged due to the oxidization of phenolic compounds, this reaction is not a definitive method of identification or determining a mushroom's potency.[125][93]: 56–58 

History Edit

Early Edit

 
Mayan "mushroom stones" of Guatemala

There is evidence to suggest that psychoactive mushrooms have been used by humans in religious ceremonies for thousands of years. 6,000-year-old pictographs discovered near the Spanish town of Villar del Humo illustrate several mushrooms that have been tentatively identified as Psilocybe hispanica, a hallucinogenic species native to the area.[131] The rock art was also discovered in Tassili, Algeria, and is believed to depict psychedelic mushrooms and the transformation of the user under their influence. The paintings are said to date back to 9000-7000 BC.[132] Archaeological artifacts from Mexico, as well as the so-called Mayan "mushroom stones" of Guatemala have also been interpreted by some scholars as evidence for ritual and ceremonial usage of psychoactive mushrooms in the Mayan and Aztec cultures of Mesoamerica.[93]: 11  In Nahuatl, the language of the Aztecs, the mushrooms were called teonanácatl, or "God's flesh". Following the arrival of Spanish explorers to the New World in the sixteenth century, chroniclers reported the use of mushrooms by the natives for ceremonial and religious purposes. According to the Dominican friar Diego Durán in The History of the Indies of New Spain (published c. 1581), mushrooms were eaten in festivities conducted on the occasion of the accession to the throne of Aztec emperor Moctezuma II in 1502. The Franciscan friar Bernardino de Sahagún wrote of witnessing mushroom usage in his Florentine Codex (published 1545–1590),[133]: 164  and described how some merchants would celebrate upon returning from a successful business trip by consuming mushrooms to evoke revelatory visions.[134]: 118  After the defeat of the Aztecs, the Spanish forbade traditional religious practices and rituals that they considered "pagan idolatry", including ceremonial mushroom use. For the next four centuries, the Indians of Mesoamerica hid their use of entheogens from the Spanish authorities.[133]: 165 

Although dozens of species of psychedelic mushrooms are found in Europe, there is little documented usage of these species in Old World history besides the use of Amanita muscaria among Siberian peoples.[135][136] The few existing historical accounts about psilocybin mushrooms typically lack sufficient information to allow species identification, and usually refer to the nature of their effects. For example, Flemish botanist Carolus Clusius (1526–1609) described the bolond gomba (crazy mushroom), used in rural Hungary to prepare love potions. English botanist John Parkinson included details about a "foolish mushroom" in his 1640 herbal Theatricum Botanicum.[137]: 10–12  The first reliably documented report of intoxication with Psilocybe semilanceata—Europe's most common and widespread psychedelic mushroom—involved a British family in 1799, who prepared a meal with mushrooms they had picked in London's Green Park.[137]: 16 

Modern Edit

 
Albert Hofmann (shown here in 1993) purified psilocybin and psilocin from Psilocybe mexicana in the late 1950s
 
The increasing availability of information on growing techniques made it possible for amateurs to grow psilocybin mushrooms (Psilocybe cubensis pictured) without access to laboratory equipment

American banker and amateur ethnomycologist R. Gordon Wasson and his wife Valentina P. Wasson, a physician, studied the ritual use of psychoactive mushrooms by the native population in the Mazatec village Huautla de Jiménez, Mexico. In 1957, Wasson described the psychedelic visions that he experienced during these rituals in "Seeking the Magic Mushroom", an article published in the popular American weekly Life magazine.[138] Later the same year they were accompanied on a follow-up expedition by French mycologist Roger Heim, who identified several of the mushrooms as Psilocybe species.[139]

Heim cultivated the mushrooms in France and sent samples for analysis to Albert Hofmann, a chemist employed by the Swiss pharmaceutical company Sandoz (now Novartis). Hofmann—who had synthesized lysergic acid diethylamide (LSD) in 1938—led a research group that isolated and identified the psychoactive alkaloids psilocybin and psilocin from Psilocybe mexicana, publishing their results in 1958.[134]: 128  The team was aided in the discovery process by Hofmann's willingness to ingest mushroom extracts to help verify the presence of the active compounds.[134]: 126–127 

Next, Hofmann's team synthesized several structural analogs of these compounds to examine how these structural changes would affect psychoactivity. This research led to the development of ethocybin and CZ-74. Because the physiological effects of these compounds last only about three and a half hours (about half as long as psilocybin), they proved more manageable than the latter for use in psycholytic therapy.[27]: 237  Sandoz also marketed and sold pure psilocybin under the name Indocybin to clinicians and researchers worldwide.[133]: 166  There were no reports of serious complications when psilocybin was used in this way.[1]

In the early 1960s, Harvard University became a testing ground for psilocybin, through the efforts of Timothy Leary and his associates Ralph Metzner and Richard Alpert (who later changed his name to Ram Dass). Leary obtained synthesized psilocybin from Hofmann through Sandoz Pharmaceuticals. Some studies, such as the Concord Prison Experiment, suggested promising results using psilocybin in clinical psychiatry.[6][140] According to a 2008 review of safety guidelines in human hallucinogenic research, however, Leary and Alpert's well-publicized termination from Harvard and later advocacy of hallucinogen use "further undermined an objective scientific approach to studying these compounds".[141] In response to concerns about the increase in unauthorized use of psychedelic drugs by the general public, psilocybin and other hallucinogenic drugs suffered negative press and faced increasingly restrictive laws. In the United States, laws were passed in 1966 that prohibited the production, trade, or ingestion of hallucinogenic drugs; Sandoz stopped producing LSD and psilocybin the same year.[97] In 1970, Congress passed "The Federal Comprehensive Drug Abuse Prevention and Control Act" that made LSD, peyote, psilocybin and other hallucinogens illegal to use for any and all purposes, including scientific research.[142] United States politicians' agenda against LSD usage had swept psilocybin along with it into the Schedule I category of illicit drugs. Such restrictions on the use of these drugs in human research made funding for such projects difficult to obtain, globally, and scientists who worked with psychedelic drugs faced being "professionally marginalized".[143] Although Hofmann tested these compounds on himself, never advocated their legalization or medical use. In his 1979 book LSD — mein Sorgenkind ("LSD — my problem child"), Hofmann described the problematic use of these hallucinogens as inebriants.[134]: 79–116 

Despite the legal restrictions on psilocybin use, the 1970s witnessed the emergence of psilocybin as the "entheogen of choice".[144]: 276  This was due in large part to a wide dissemination of information on the topic, which included works such as those by author Carlos Castaneda, and several books that taught the technique of growing psilocybin mushrooms. One of the most popular of this latter group was published in 1976 under the pseudonyms O.T. Oss and O.N. Oeric by Jeremy Bigwood, Dennis J. McKenna, K. Harrison McKenna, and Terence McKenna, entitled Psilocybin: Magic Mushroom Grower's Guide. Over 100,000 copies were sold by 1981.[145] As ethnobiologist Jonathan Ott explains, "These authors adapted San Antonio's technique (for producing edible mushrooms by casing mycelial cultures on a rye grain substrate; San Antonio 1971) to the production of Psilocybe [Stropharia] cubensis. The new technique involved the use of ordinary kitchen implements, and for the first time the layperson was able to produce a potent entheogen in his own home, without access to sophisticated technology, equipment or chemical supplies."[144]: 290  San Antonio's technique describes a method to grow the common edible mushroom Agaricus bisporus[146]

Because of a lack of clarity about laws about psilocybin mushrooms, specifically in the form of sclerotia (also known as "truffles"), European retailers in the late 1990s and early 2000s commercialized and marketed them in smartshops in the Netherlands and the UK, and online. Several websites[f] emerged that have contributed to the accessibility of information on description, use, effects and exchange of experiences among users. Since 2001, six EU countries have tightened their legislation on psilocybin mushrooms in response to concerns about their prevalence and increasing usage.[48] In the 1990s, hallucinogens and their effects on human consciousness were again the subject of scientific study, particularly in Europe. Advances in neuropharmacology and neuropsychology, and the availability of brain imaging techniques have provided impetus for using drugs like psilocybin to probe the "neural underpinnings of psychotic symptom formation including ego disorders and hallucinations".[13] Recent studies in the United States have attracted attention from the popular press and thrust psilocybin back into the limelight.[147][148]

Society and culture Edit

Legal status Edit

Further information: Legal status of psilocybin mushrooms and Psilocybin decriminalization in the United States
This section is an excerpt from Legal status of psilocybin mushrooms.[edit]

The legal status of unauthorised actions with psilocybin mushrooms varies worldwide. Psilocybin and psilocin are listed as Schedule I drugs under the United Nations 1971 Convention on Psychotropic Substances.[149] Schedule I drugs are defined as drugs with a high potential for abuse or drugs that have no recognized medical uses. However, psilocybin mushrooms have had numerous medicinal[150][151][152] and religious uses in dozens of cultures throughout history and have a significantly lower potential for abuse than other Schedule I drugs.[153]

Psilocybin mushrooms are not regulated by UN treaties.[154] Many countries, however, have some level of regulation or prohibition of psilocybin mushrooms (for example, the US Psychotropic Substances Act, the UK Misuse of Drugs Act 1971, and the Canadian Controlled Drugs and Substances Act).

In some jurisdictions, Psilocybe spores are legal to sell and possess, because they contain neither psilocybin nor psilocin.[citation needed] In other jurisdictions, they are banned because they are items that are used in drug manufacture. A few jurisdictions (such as the US states of California, Georgia and Idaho) have specifically prohibited the sale and possession of psilocybin mushroom spores. Cultivation of psilocybin mushrooms is considered drug manufacture in most jurisdictions and is often severely penalized, though some countries and one US state (New Mexico) has ruled that growing psilocybin mushrooms does not qualify as "manufacturing" a controlled substance.[citation needed]

Advocacy for tolerance Edit

Despite being illegal in many typically Western countries, such as the UK, Australia and some US states, less conservative governments opt to nurture the legal use of psilocybin and other psychedelic drugs. In Amsterdam, Netherlands, authorities provide education and promotion on the safe use of psychedelic drugs, such as psilocybin, in an aim to reduce public harm.[155] Similarly, religious groups like America's Uniao do Vegetal, UDV,[156] use psychedelics in traditional ceremonies.[157] From 1st July 2023, the Australian medicines regulator has permitted psychiatrists to prescribe psilocybin for the therapeutic treatment of post-traumatic stress disorder.[158]

Advocates for legalization argue there is a lack of evidence of harm,[159][160] and potential use in treating certain mental health conditions. Research is difficult to conduct because of the legal status of psychoactive substances.[161] Advocates for legalization also promote the utility of "ego dissolution"[156] and argue bans are cultural discrimination against traditional users.[162]

Usage Edit

 
Dried Psilocybe mushrooms showing the characteristic blue bruising on the stems

A 2009 national survey of drug use by the US Department of Health and Human Services concluded that the number of first-time psilocybin mushroom users in the United States was roughly equivalent to the number of first-time users of cannabis.[163] In European countries, the lifetime prevalence estimates of psychedelic mushroom usage among young adults (15–34 years) range from 0.3% to 14.1%.[164]

In modern Mexico, traditional ceremonial use survives among several indigenous groups, including the Nahuas, the Matlatzinca, the Totonacs, the Mazatecs, Mixes, Zapotecs, and the Chatino. Although hallucinogenic Psilocybe species are abundant in low-lying areas of Mexico, most ceremonial use takes places in mountainous areas of elevations greater than 1,500 meters (4,900 ft). Guzmán suggests this is a vestige of Spanish colonial influence from several hundred years earlier, when mushroom use was persecuted by the Catholic Church.[165]

Current research Edit

See also: Psychedelic therapy

Psilocybin has been a subject of clinical research since the early 1960s, when the Harvard Psilocybin Project evaluated the potential value of psilocybin as a treatment for certain personality disorders.[166] Beginning in the 2000s, psilocybin has been investigated for its possible role in the treatment of nicotine dependence, alcohol dependence, obsessive–compulsive disorder (OCD), cluster headache, cancer-related existential distress[79][167] anxiety disorders, and certain mood disorders.[133]: 179–81 [168][169] In 2018, the United States Food and Drug Administration (FDA) granted breakthrough therapy designation for psilocybin-assisted therapy for treatment-resistant depression.[170][171] A systematic review published in 2021 found that the use of psilocybin as a pharmaceutical substance was associated with reduced intensity of depression symptoms.[172] The role of psilocybin as a possible psychoplastogen is also being examined.[86][87][88]

See also Edit

Notes Edit

  1. ^ Synonyms and alternate spellings include: 4-PO-DMT (PO: phosphate; DMT: dimethyltryptamine), psilocybine, psilocibin, psilocybinum, psilotsibin, psilocin phosphate ester, and indocybin.[5]
  2. ^ Percentages are derived from a non-blind clinical study of 30 individuals who were given a dosage of 8–12 milligrams of psilocybin; from Passie (2002),[1] citing Quentin (1960).[18]
  3. ^ The academic communities' approval for the methodology employed is exemplified by the quartet of commentaries published in the journal Psychopharmacology titled "Commentary on: Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual experience by Griffiths et al.", by HD Kleber (pp. 291–292), DE Nichols (pp. 284–286), CR Schuster (pp. 289–290), and SH Snyder (pp. 287–288).
  4. ^ One of the reported fatalities, that of a 22-year-old French man who died in 1993,[55] was later challenged in the literature by Jochen Gartz and colleagues, who concluded "the few reported data concerning the victim are insufficient to exclude other possible causes of the fatality".[56]
  5. ^ Subjective effects are "feelings, perceptions, and moods personally experienced by an individual"; they are often assessed using methods of self-report, including questionnaires. Behavioral effects, in contrast, can be observed directly.[89]
  6. ^ The EMCDDA lists the general-purpose websites Erowid, Lycaeum, Mycotopia, The Shroomery, MushroomJohn and The Entheogen Review. Regional sites focusing on hallucinogenic mushrooms listed were Copenhagen Mushroom Link (Denmark), Champis (France), Daath (Hungary), Delysid (Spain), Enteogeneos (Portugal), Kouzelné houbičky (Czech Republic), Norshroom (Norway), Planetahongo (Spain), Svampinfo (Sweden), and Taikasieniforum (Finland). It also listed Magic-Mushrooms.net. The report detailed several additional sites selling spore prints in 2006, but noted that many of these had ceased operation.

References Edit

Citations Edit

  1. ^ a b c d e f g h i j Passie T, Seifert J, Schneider U, Emrich HM (2002). "The pharmacology of psilocybin". Addiction Biology. 7 (4): 357–364. doi:10.1080/1355621021000005937. PMID 14578010. S2CID 12656091.
  2. ^ Anvisa (July 24, 2023). "RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published July 25, 2023). from the original on August 27, 2023. Retrieved August 27, 2023.
  3. ^ a b Merck Index, 11th Edition, 7942
  4. ^ "Psilocybine". PubChem, US National Library of Medicine. August 27, 2022. Retrieved August 29, 2022.
  5. ^ "Psilocybine – Compound Summary". PubChem. National Library of Medicine. from the original on September 25, 2012. Retrieved December 4, 2011.
  6. ^ a b Leary T, Litwin GH, Metzner R (1963). "Reactions to psilocybin administered in a supportive environment". Journal of Nervous and Mental Disease. 137 (6): 561–573. doi:10.1097/00005053-196312000-00007. PMID 14087676. S2CID 39777572.
  7. ^ Berge JT (1999). "Breakdown or breakthrough? A history of European research into drugs and creativity". Journal of Creative Behavior. 33 (4): 257–276. doi:10.1002/j.2162-6057.1999.tb01406.x. ISSN 0022-0175.
  8. ^ a b c d e f g h i j k l m van Amsterdam J, Opperhuizen A, van den Brink W (2011). (PDF). Regulatory Toxicology and Pharmacology. 59 (3): 423–429. doi:10.1016/j.yrtph.2011.01.006. PMID 21256914. Archived from the original (PDF) on January 9, 2015.
  9. ^ "Hallucinogenic Drug Psilocybin Eases Existential Anxiety in People With Life-Threatening Cancer". Johns Hopkins. December 1, 2016. from the original on April 7, 2021. Retrieved April 9, 2019.
  10. ^ Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R (June 15, 2011). "Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects". Johns Hopkins. 218 (4): 649–665. doi:10.1007/s00213-011-2358-5. PMC 3308357. PMID 21674151.
  11. ^ a b c Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX (2004). "Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study" (PDF). Psychopharmacology. 172 (2): 145–156. doi:10.1007/s00213-003-1640-6. PMID 14615876. S2CID 15263504. (PDF) from the original on April 18, 2020. Retrieved April 10, 2019.
  12. ^ a b c Ballesteros S, Ramón MF, Iturralde MJ, Martínez-Arrieta R (2006). "Natural sources of drugs of abuse: magic mushrooms". In Cole SM (ed.). New Research on Street Drugs. New York, New York: Nova Science Publishers. pp. 167–186. ISBN 978-1-59454-961-8. from the original on April 4, 2017. Retrieved February 27, 2016.
  13. ^ a b Studerus E, Kometer M, Hasler F, Vollenweider FX (2011). "Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies". Journal of Psychopharmacology. 25 (11): 1434–1452. doi:10.1177/0269881110382466. PMID 20855349. S2CID 22923427.
  14. ^ a b MacLean KA, Johnson MW, Griffiths RR (2011). "Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness". Journal of Psychopharmacology. 25 (11): 1453–1461. doi:10.1177/0269881111420188. PMC 3537171. PMID 21956378.
  15. ^ Griffiths RR, Johnson MW, Richards WA, Richards BD, Jesse R, MacLean KA, et al. (January 2018). "Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors". Journal of Psychopharmacology. 32 (1): 49–69. doi:10.1177/0269881117731279. PMC 5772431. PMID 29020861.
  16. ^ "Psilocybin (from magic mushrooms) plus meditation and spiritual training leads to lasting changes in positive traits". January 19, 2018. from the original on February 21, 2019. Retrieved February 21, 2019.
  17. ^ Frecska E, Luna LE (2006). "The adverse effects of hallucinogens from intramural perspective" (PDF). Neuropsychopharmacologia Hungarica. 8 (4): 189–200. PMID 17211054. (PDF) from the original on September 16, 2018. Retrieved December 27, 2011.
  18. ^ Quentin AM (1960). La Psilocybine en Psychiatrie Clinique et Experimentale [Psilocybin in Clinical and Experimental Psychiatry] (PhD thesis) (in French). Paris, France: Paris University Medical Dissertation.
  19. ^ See for example:
    • Isbell H (1959). "Comparison of the reactions induced by psilocybin and LSD-25 in man". Psychopharmacologia. 1 (1): 29–38. doi:10.1007/BF00408109. PMID 14405870. S2CID 19508675.
    • Hollister LE, Prusmack JJ, Paulsen A, Rosenquist N (1960). "Comparison of three psychotropic drugs (psilocybin, JB-329, and IT-290) in volunteer subjects". Journal of Nervous and Mental Disease. 131 (5): 428–434. doi:10.1097/00005053-196011000-00007. PMID 13715375. S2CID 8255131.
    • Malitz S, Esecover H, Wilkens B, Hoch PH (1960). "Some observations on psilocybin, a new hallucinogen, in volunteer subjects". Comprehensive Psychiatry. 1: 8–17. doi:10.1016/S0010-440X(60)80045-4. PMID 14420328.[permanent dead link]
    • Rinkel M, Atwell CR, Dimascio A, Brown J (1960). "Experimental psychiatry. V. Psilocybine, a new psychotogenic drug". New England Journal of Medicine. 262 (6): 295–297. doi:10.1056/NEJM196002112620606. PMID 14437505.
    • Parashos AJ (1976). "The psilocybin-induced "state of drunkenness" in normal volunteers and schizophrenics". Behavioral Neuropsychiatry. 8 (1–12): 83–86. PMID 1052267.
  20. ^ Heimann H (1994). "Experience of time and space in model psychoses". In Pletscher A, Ladewig D (eds.). 50 Years of LSD. Current Status and Perspectives of Hallucinogens. New York, New York: The Parthenon Publishing Group. pp. 59–66. ISBN 978-1-85070-569-7.
  21. ^ a b Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, Hell D, Flohr H, Vollenweider FX (2007). "Effects of psilocybin on time perception and temporal control of behaviour in humans". Journal of Psychopharmacology. 21 (1): 50–64. doi:10.1177/0269881106065859. PMID 16714323. S2CID 3165579.
  22. ^ Wackermann J, Wittmann M, Hasler F, Vollenweider FX (2008). "Effects of varied doses of psilocybin on time interval reproduction in human subjects". Neuroscience Letters. 435 (1): 51–55. doi:10.1016/j.neulet.2008.02.006. PMID 18325673. S2CID 22789140.
  23. ^ Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX (2005). "Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors" (PDF). Journal of Cognitive Neuroscience. 17 (10): 1497–1508. doi:10.1162/089892905774597191. PMID 16269092. S2CID 9790150. (PDF) from the original on August 16, 2019. Retrieved August 16, 2019.
  24. ^ Harrington DL, Haaland KY (1999). "Neural underpinnings of temporal processing: a review of focal lesion, pharmacological, and functional imaging research". Reviews in the Neurosciences. 10 (2): 91–116. doi:10.1515/REVNEURO.1999.10.2.91. PMID 10658954. S2CID 25960626.
  25. ^ a b Coull JT, Cheng RK, Meck WH (2011). "Neuroanatomical and neurochemical substrates of timing". Neuropsychopharmacology. 36 (1): 3–25. doi:10.1038/npp.2010.113. PMC 3055517. PMID 20668434.
  26. ^ a b Attema-de Jonge ME, Portier CB, Franssen EJ (2007). "Automutilatie na gebruik van hallucinogene paddenstoelen" [Automutilation after consumption of hallucinogenic mushrooms]. Nederlands Tijdschrift voor Geneeskunde (in Dutch). 151 (52): 2869–2872. PMID 18257429.
  27. ^ a b c Stafford PJ (1992). Psychedelics Encyclopedia (3rd ed.). Berkeley, California: Ronin Publishing. ISBN 978-0-914171-51-5.
  28. ^ "Drug Addictions, Hallucinogens and Shamanism: the View from Anthropology - Document - Gale Academic OneFile". from the original on August 23, 2021. Retrieved August 23, 2021.
  29. ^ a b c d Batchelder T (2001). "Drug Addictions, Hallucinogens and Shamanism: the View from Anthropology". Drug Addictions, Hallucinogens and Shamanism. Townsend Letter for Doctors and Patients. 217: 74–77. from the original on October 19, 2021. Retrieved August 23, 2021 – via Gale Academic OneFile.
  30. ^ Leary T (2007). The psychedelic experience : a manual based on the Tibetan book of the dead. Ralph Metzner, Ram Dass, activeth century Karma-gliṅ-pa. New York: Citadel Press. ISBN 978-0-8065-1652-3. OCLC 318713242. from the original on October 19, 2021. Retrieved August 23, 2021.
  31. ^ Hendricks PS (October 2020). "Psilocybin-assisted group therapy: A new hope for demoralization". eClinicalMedicine. 27: 100557. doi:10.1016/j.eclinm.2020.100557. PMC 7549063. PMID 33073220.
  32. ^ Winkelman MJ (2007). "Therapeutic bases of psychedelic medicines: psychointegrative effects". In Winkelman MJ, Roberts TB (eds.). Psychedelic Medicine: New Evidence for Hallucinogenic Substances as Treatments. Vol. 1. Westport, Connecticut: Praeger. pp. 1–19. ISBN 978-0-275-99024-4.
  33. ^ McKenna T (1993). Food of the Gods: The Search for the Original Tree of Knowledge. A Radical History of Plants, Drugs, and Human Evolution. New York, New York: Bantam Books. ISBN 978-0-553-37130-7.
  34. ^ James W (1902). The Varieties of Religious Experience. New York, New York: Simon & Schuster. ISBN 978-0-684-84297-4.
  35. ^ Metzner R (1998). "Hallucinogenic drugs and plants in psychotherapy and shamanism" (PDF). Journal of Psychoactive Drugs. 30 (4): 333–341. CiteSeerX 10.1.1.509.4769. doi:10.1080/02791072.1998.10399709. PMID 9924839. (PDF) from the original on September 21, 2017. Retrieved October 26, 2017.
  36. ^ Pahnke WN, Richards W (1966). "Implications of LSD and experimental mysticism". Journal of Religion and Health. 5 (3): 175–208. doi:10.1007/BF01532646. PMID 24424798. S2CID 18464414.
  37. ^ Pahnke WN (1966). "Drugs and mysticism". International Journal of Parapsychology. 8 (2): 295–315.
  38. ^ a b Griffiths R, Richards W, Johnson M, McCann U, Jesse R (2008). (PDF). Journal of Psychopharmacology. 22 (6): 621–632. doi:10.1177/0269881108094300. PMC 3050654. PMID 18593735. Archived from the original (PDF) on July 22, 2008. Retrieved July 3, 2008.
  39. ^ Smith H (2000). Cleansing the Doors of Perception: The Religious Significance of Entheogenic Plants and Chemicals. New York, New York: Jeremy P. Tarcher/Putnam. p. 101. ISBN 978-1-58542-034-6.
  40. ^ a b Doblin R (1991). "Pahnke's "Good Friday Experiment": a long-term follow-up and methodological critique". Journal of Transpersonal Psychology. 23 (1): 1–25.
  41. ^ Richards WA (2008). "The phenomenology and potential religious import of states of consciousness facilitated by psilocybin". Archive for the Psychology of Religion. 30 (1): 189–199. doi:10.1163/157361208X317196. S2CID 144969540.
  42. ^ Griffiths RR, Richards WA, McCann U, Jesse R (2006). (PDF). Psychopharmacology. 187 (3): 268–283. doi:10.1007/s00213-006-0457-5. PMID 16826400. S2CID 7845214. Archived from the original (PDF) on November 9, 2011.
  43. ^ "Press release: Griffiths psilocybin". Johns Hopkins Medicine. July 11, 2006. from the original on July 16, 2011. Retrieved July 12, 2006.
  44. ^ Hood Jr RW (1975). "The construction and preliminary validation of a measure of reported mystical experience". Journal for the Scientific Study of Religion. 14 (1): 29–41. doi:10.2307/1384454. JSTOR 1384454. S2CID 147200008.
  45. ^ Smith M (July 12, 2006). "Medical News: Psilocybin Viewed as Therapy or Research Tool". Medpagetoday.com. from the original on October 5, 2008. Retrieved February 12, 2011.
  46. ^ a b Carhart-Harris, R; Nutt, D (2010). "User perceptions of the benefits and harms of hallucinogenic drug use: a web-based questionnaire study". Journal of Substance Abuse. 15 (4): 283–300. doi:10.3109/14659890903271624. S2CID 56427651.
  47. ^ "Paul McHugh reviews Don Lattin's "The Harvard Psychedelic Club."". commentarymagazine.com. April 1, 2010. from the original on April 10, 2019. Retrieved April 10, 2019.
  48. ^ a b Hillebrand J, Olszewski D, Sedefov R (2006). Hallucinogenic Mushrooms: An Emerging Trend Case Study (PDF) (Report). Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). ISBN 92-9168-249-7. (PDF) from the original on March 29, 2012. Retrieved September 8, 2011.
  49. ^ Pagliaro LA, Pagliaro AM (2012). Handbook of Child and Adolescent Drug and Substance Abuse: Pharmacological, Developmental, and Clinical Considerations (2nd ed.). Hoboken, New Jersey: John Wiley & Sons. p. 199. ISBN 978-0-470-63906-1. from the original on April 3, 2017. Retrieved February 27, 2016.
  50. ^ Schaefer C (2001). Drugs During Pregnancy and Lactation: Handbook of Prescription Drugs and Comparative Risk Assessment. Amsterdam, the Netherlands: Elsevier. p. 222. ISBN 978-0-444-50763-1. from the original on April 3, 2017. Retrieved February 27, 2016.
  51. ^ a b Reinert JP, Colunga K, Etuk A, Richardson V, Dunn RL (August 2020). "Management of overdoses of salvia, kratom, and psilocybin mushrooms: a literature review". Expert Rev Clin Pharmacol (Review). 13 (8): 847–856. doi:10.1080/17512433.2020.1794811. PMID 32648791. S2CID 220472473.
  52. ^ a b O'Neil MJ, Smith A, Heckelman PE, Obenchain JR, Gallipeau JR, D'Arecca MA, eds. (2001). The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals (13th ed.). Whitehouse Station, New Jersey: Merck. p. 1419. ISBN 978-0-911910-13-1.
  53. ^ Gable RS (2004). "Comparison of acute lethal toxicity of commonly abused psychoactive substances" (PDF). Addiction. 99 (6): 686–696. doi:10.1111/j.1360-0443.2004.00744.x. PMID 15139867. (PDF) from the original on August 10, 2006. Retrieved November 16, 2011.
  54. ^ Strassman R, Wojtowicz S, Luna LE, Frecska E (2008). Inner Paths to Outer Space: Journeys to Alien Worlds through Psychedelics and Other Spiritual Technologies. Rochester, Vermont: Park Street Press. p. 147. ISBN 978-1-59477-224-5. from the original on April 4, 2017. Retrieved February 27, 2016.
  55. ^ Gérault A, Picart D (1996). "Intoxication mortelle à la suite de la consommation volontaire et en groupe de champignons hallucinogènes" [Fatal poisoning after a group of people voluntarily consumed hallucinogenic mushrooms]. Bulletin de la Société Mycologique de France (in French). 112: 1–14.
  56. ^ Gartz J, Samorini G, Festi F (1996). . Eluesis. 6: 40–41. Archived from the original on April 5, 2012.
  57. ^ Peden NR, Pringle SD, Crooks J (1982). "The problem of psilocybin mushroom abuse". Human Toxicology. 1 (4): 417–424. doi:10.1177/096032718200100408. PMID 7173927. S2CID 7453965.
  58. ^ a b Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D (1998). (PDF). NeuroReport. 9 (17): 3897–3902. doi:10.1097/00001756-199812010-00024. PMID 9875725. S2CID 37706068. Archived from the original (PDF) on March 3, 2019.
  59. ^ Hyde C, Glancy P, Omerod P, Hall D, Taylor GS (1978). "Abuse of indigenous psilocybin mushrooms: a new fashion and some psychiatric complications". British Journal of Psychiatry. 132 (6): 602–604. doi:10.1192/bjp.132.6.602. PMID 566144. S2CID 20020560.
  60. ^ Mack RB (1983). "Phenomenally phunny phungi – psilocybin toxicity". New Castle Medical Journal. 44 (10): 639–640. PMID 6580536.
  61. ^ Simeon D (2004). "Depersonalisation disorder: a contemporary overview". CNS Drugs. 18 (6): 343–354. doi:10.2165/00023210-200418060-00002. PMID 15089102. S2CID 18506672.
  62. ^ Nielen RJ, van der Heijden FM, Tuinier S, Verhoeven WM (January 2004). "Khat and mushrooms associated with psychosis". The World Journal of Biological Psychiatry. 5 (1): 49–53. doi:10.1080/15622970410029908. PMID 15048636. S2CID 44321700.
  63. ^ Geyer MA (1998). "Behavioral studies of hallucinogenic drugs in animals: implications for schizophrenia research". Pharmacopsychiatry. 31 (S2): 73–79. doi:10.1055/s-2007-979350. PMID 9754837.
  64. ^ a b Vollenweider FX, Geyer MA (2001). "A systems model of altered consciousness: integrating natural and drug-induced psychoses". Brain Research Bulletin. 56 (5): 495–507. doi:10.1016/S0361-9230(01)00646-3. PMID 11750795. S2CID 230298.
  65. ^ Geyer MA, Vollenweider FX (2008). "Serotonin research: contributions to understanding psychoses". Trends in Pharmacological Sciences. 29 (9): 445–453. doi:10.1016/j.tips.2008.06.006. PMID 19086254.
  66. ^ Myers LS, Watkins SS, Carter TJ (1998). "Flashbacks in theory and practice" (PDF). The Heffter Review of Psychedelic Research. 1: 51–57. (PDF) from the original on September 27, 2011. Retrieved August 14, 2011.
  67. ^ Gable RS (2006). "Acute toxicity of drugs versus regulatory status". In Fish JM (ed.). Drugs and Society: U.S. Public Policy. Lanham, Maryland: Rowman & Littlefield. pp. 149–162, Table 7.1 "Safety Ratio and Dependence Potential of Psychoactive Drugs". ISBN 978-0-7425-4245-7. from the original on January 7, 2012.
  68. ^ Nicholas LG, Ogame K (2006). Psilocybin Mushroom Handbook: Easy Indoor and Outdoor Cultivation. Oakland, California: Quick American Archives. p. 164. ISBN 978-0-932551-71-9. from the original on April 4, 2017. Retrieved February 27, 2016.
  69. ^ Passie T, Halpern JH, Stichtenoth, Emrich HM, Hintzen A (2008). "The pharmacology of lysergic acid diethyamide: a review". CNS Neuroscience & Therapeutics. 14 (4): 295–314. doi:10.1111/j.1755-5949.2008.00059.x. PMC 6494066. PMID 19040555.
  70. ^ a b Halberstadt AL, Geyer MA (2011). "Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens". Neuropharmacology. 61 (3): 364–381. doi:10.1016/j.neuropharm.2011.01.017. PMC 3110631. PMID 21256140.
  71. ^ Chen CY, Storr CL, Anthony JC (2008). "Early-onset drug use and risk for drug dependence problems". Addictive Behaviors. 34 (3): 319–322. doi:10.1016/j.addbeh.2008.10.021. PMC 2677076. PMID 19022584.
  72. ^ van Amsterdam J, Opperhuizen A, Koeter M, van den Brink W (2010). "Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population". European Addiction Research. 16 (4): 202–207. doi:10.1159/000317249. PMID 20606445. S2CID 207669364.
  73. ^ Nutt DJ, King LA, Phillips LD (2010). "Drug harms in the UK: a multicriteria decision analysis". Lancet. 376 (9752): 1558–1565. CiteSeerX 10.1.1.690.1283. doi:10.1016/S0140-6736(10)61462-6. PMID 21036393. S2CID 5667719.
  74. ^ Azmitia EC (2010). "Evolution of serotonin: sunlight to suicide". In Müller CP, Jacobs BL (eds.). Handbook of the Behavioral Neurobiology of Serotonin. London, UK: Academic Press. p. 7. ISBN 978-0-12-374634-4. from the original on April 4, 2017. Retrieved February 27, 2016.
  75. ^ a b c d Wurst M, Kysilka R, Flieger M (2002). "Psychoactive tryptamines from Basidiomycetes". Folia Microbiologica. 47 (1): 3–27. doi:10.1007/BF02818560. PMID 11980266. S2CID 31056807.
  76. ^ a b "Psilocybine". Hazardous Substances Data Bank. U.S. National Library of Medicine. from the original on August 13, 2018. Retrieved November 21, 2011.
  77. ^ Sherwood, A. M.; Kargbo, R. B.; Kaylo, K. W.; Cozzi, N. V.; Meisenheimer, P.; Kaduk, J. A. (January 1, 2022). "Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples". Acta Crystallographica Section C: Structural Chemistry. 78 (1): 36–55. doi:10.1107/S2053229621013164. ISSN 2053-2296. PMC 8725723. PMID 34982048.
  78. ^ a b Anastos N, Barnett NW, Pfeffer FM (2006). "Investigation into the temporal stability of aqueous standard solutions of psilocin and psilocybin using high performance liquid chromatography". Science & Justice. 46 (2): 91–96. doi:10.1016/S1355-0306(06)71579-9. PMID 17002211.
  79. ^ a b Serreau, Raphaël; Amirouche, Ammar; Benyamina, Amine; Berteina-Raboin, Sabine (2023). "A Review of Synthetic Access to Therapeutic Compounds Extracted from Psilocybe". Pharmaceuticals (Basel). 16 (1): 40. doi:10.3390/ph16010040. PMC 9867295. PMID 36678537.
  80. ^ a b c Fricke J, Blei F, Hoffmeister D (September 2017). "Enzymatic synthesis of psilocybin". Angewandte Chemie. 56 (40): 12352–12355. doi:10.1002/anie.201705489. PMID 28763571.
  81. ^ Agurell S, Nilsson JL (1968). "Biosynthesis of psilocybin. Part II. Incorporation of labelled tryptamine derivatives". Acta Chemica Scandinavica. 22 (4): 1210–1218. doi:10.3891/acta.chem.scand.22-1210. PMID 5750023.
  82. ^ a b Reynolds HT, Vijayakumar V, Gluck-Thaler E, Korotkin HB, Matheny PB, Slot JC (April 2018). "Horizontal gene cluster transfer increased hallucinogenic mushroom diversity". Evolution Letters. 2 (2): 88–101. doi:10.1002/evl3.42. PMC 6121855. PMID 30283667.
  83. ^ Satyanarayana M (October 7, 2019). "Modified E. coli pump out psilocybin". Chemical & Engineering News. 97 (39): 11. doi:10.1021/cen-09739-scicon9. S2CID 208747979. from the original on December 3, 2019. Retrieved December 3, 2019.
  84. ^ Milne, N.; Thomsen, P.; Knudsen, N.; Rubaszka, P.; Kristensen, M.; Borodina, I. (2020). "Metabolic engineering of Saccharomyces cerevisiae for the de novo production of psilocybin and related tryptamine derivatives". Metabolic Engineering. 60: 25–36. doi:10.1016/j.ymben.2019.12.007. PMC 7232020. PMID 32224264.
  85. ^ Wong, Garrett; Lim, Li Rong; Tan, Yong Quan; Go, Maybelle Kho; Bell, David J.; Freemont, Paul S.; Yew, Wen Shan (2022). "Reconstituting the complete biosynthesis of D-lysergic acid in yeast". Nature Communications. 13 (1): 712. Bibcode:2022NatCo..13..712W. doi:10.1038/s41467-022-28386-6. PMC 8821704. PMID 35132076.
  86. ^ a b Vargas, MV; Meyer, R; Avanes, AA; Rus, M; Olson, DE (2021). "Psychedelics and Other Psychoplastogens for Treating Mental Illness". Frontiers in Psychiatry. 12: 727117. doi:10.3389/fpsyt.2021.727117. PMC 8520991. PMID 34671279.
  87. ^ a b Olson, David E (September 19, 2018). "Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics". Journal of Experimental Neuroscience. 12: 1179069518800508. doi:10.1177/1179069518800508. ISSN 1179-0695. PMC 6149016. PMID 30262987.
  88. ^ a b de Vos, Cato M. H.; Mason, Natasha L.; Kuypers, Kim P. C. (2021). "Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics". Frontiers in Psychiatry. 12: 1575. doi:10.3389/fpsyt.2021.724606. ISSN 1664-0640. PMC 8461007. PMID 34566723.
  89. ^ Karch SB (2007). Pharmacokinetics and Pharmacodynamics of Abused Drugs. Boca Raton, Florida: CRC Press. p. 148. ISBN 978-1-4200-5458-3. from the original on April 4, 2017. Retrieved February 27, 2016.
  90. ^ "PDSP Ki Database". PDSP. from the original on May 9, 2021. Retrieved January 20, 2020.
  91. ^ Adams Jr JD (2009). "Chemical interactions with pyramidal neurons in layer 5 of the cerebral cortex: control of pain and anxiety". Current Medicinal Chemistry. 16 (27): 3476–3279. doi:10.2174/092986709789057626. PMID 19799545.
  92. ^ Mason NL, Kuypers KP, Müller F, Reckweg J, Tse DH, Toennes SW, et al. (November 2020). "Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin". Neuropsychopharmacology. 45 (12): 2003–2011. doi:10.1038/s41386-020-0718-8. PMC 7547711. PMID 32446245.
  93. ^ a b c d e f g Stamets P (1996). Psilocybin Mushrooms of the World: An Identification Guide. Berkeley, California: Ten Speed Press. ISBN 978-0-89815-839-7.
  94. ^ a b Grieshaber AF, Moore KA, Levine B (2001). "The detection of psilocin in human urine". Journal of Forensic Sciences. 46 (3): 627–630. doi:10.1520/JFS15014J. PMID 11373000.
  95. ^ Hasler F, Bourquin D, Brenneisen R, Vollenweider FX (2002). "Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man". Journal of Pharmaceutical and Biomedical Analysis. 30 (2): 331–339. doi:10.1016/S0731-7085(02)00278-9. PMID 12191719.
  96. ^ Meyer MR, Maurer HH (2011). "Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse". Pharmacogenomics. 12 (2): 215–233. doi:10.2217/pgs.10.171. PMID 21332315.
  97. ^ a b Matsushima Y, Eguchi F, Kikukawa T, Matsuda T (2009). "Historical overview of psychoactive mushrooms". Inflammation and Regeneration. 29 (1): 47–58. doi:10.2492/inflammregen.29.47.
  98. ^ Baselt RC (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Foster City, California: Biomedical Publications. pp. 1346–1348. ISBN 978-0-9626523-7-0.
  99. ^ Beck O, Helander A, Karlson-Stiber C, Stephansson N (1998). "Presence of phenylethylamine in hallucinogenic Psilocybe mushroom: possible role in adverse reactions". Journal of Analytical Toxicology. 22 (1): 45–49. doi:10.1093/jat/22.1.45. PMID 9491968.
  100. ^ van Amsterdam J, Talhout R, Vleeming W, Opperhuizen A (2006). "Contribution of monoamine oxidase (MAO) inhibition to tobacco and alcohol addiction". Life Sciences. 79 (21): 1969–1973. doi:10.1016/j.lfs.2006.06.010. PMID 16884739.
  101. ^ Jenkins AJ (2003). "Hallucinogens". In Levine B (ed.). Principles of Forensic Toxicology (2nd ed.). Washington, D.C.: American Association for Clinical Chemistry Press. p. 281. ISBN 978-1-890883-87-4. from the original on April 3, 2017. Retrieved February 27, 2016.
  102. ^ Cole MD (2003). The Analysis of Controlled Substances. New York, Chichester: John Wiley and Sons. pp. 132–133. ISBN 978-0-471-49252-8.
  103. ^ Bresinsky A, Besl H (1989). A Colour Atlas of Poisonous Fungi: A Handbook for Pharmacists, Doctors, and Biologists. London, UK: Manson Publishing. p. 113. ISBN 978-0-7234-1576-3. from the original on April 4, 2017. Retrieved February 27, 2016.
  104. ^ Kamata T, Katagi M, Tsuchihashi H (2010). "Metabolism and toxicological analyses of hallucinogenic tryptamine analogues being abused in Japan". Forensic Toxicology. 28 (1): 1–8. doi:10.1007/s11419-009-0087-9. S2CID 45118221.
  105. ^ a b Keller T, Schneider A, Regenscheit P, Dirnhofer R, Rücker T, Jaspers J, Kisser W (1999). "Analysis of psilocybin and psilocin in Psilocybe subcubensis Guzmán by ion mobility spectrometry and gas chromatography-mass spectrometry". Forensic Science International. 99 (2): 93–105. doi:10.1016/S0379-0738(98)00168-6. PMID 10077856.
  106. ^ Pedersen-Bjergaard S, Sannes E, Rasmussen K, Tonneson F (1997). "Determination of psilocybin in Psilocybe semilanceata by capillary zone electrophoresis". Journal of Chromatography. 694 (2): 375–381. doi:10.1016/S0378-4347(97)00127-8. PMID 9252052.
  107. ^ Lee RE (1985). "A technique for the rapid isolation and identification of psilocin from psilocin/psilocybin-containing mushrooms". Journal of Forensic Sciences. 30 (3): 931–941. doi:10.1520/JFS11028J. PMID 4040953.
  108. ^ Wurst M, Kysilka R, Koza T (1992). "Analysis and isolation of indole alkaloids of fungi by high-performance liquid chromatography". Journal of Chromatography. 593 (1–2): 201–208. doi:10.1016/0021-9673(92)80287-5.
  109. ^ Saito K, Toyo'oka T, Fukushima T, Kato M, Shirota O, Goda Y (2004). "Determination of psilocin in magic mushrooms and rat plasma by liquid chromatography with fluorimetry and electrospray ionization mass spectrometry". Analytica Chimica Acta. 527 (2): 149–156. doi:10.1016/j.aca.2004.08.071.
  110. ^ a b Lindenblatt H, Kramer E, Holzmann-Erens P, Gouzoulis-Mayfrank E, Kovar K (1998). "Quantitation of psilocin in human plasma by high performance liquid chromatography and electrochemical detection: comparison of liquid-liquid extraction with automated on-line solid-phase extraction". Journal of Chromatography. 709 (2): 255–263. doi:10.1016/S0378-4347(98)00067-X. PMID 9657222.
  111. ^ Rodriguez-Cruz SE (2005). . Microgram Journal. 3 (3–4): 175–82. Archived from the original on April 29, 2011.
  112. ^ a b Sticht G, Käferstein H (2000). "Detection of psilocin in body fluids". Forensic Science International. 113 (1): 403–407. doi:10.1016/S0379-0738(00)00213-9. PMID 10978655.
  113. ^ Kysilka R (1990). "Determination of psilocin in rat urine by high-performance liquid chromatography with electrochemical detection". Journal of Chromatography. 534: 287–290. doi:10.1016/S0378-4347(00)82176-3. PMID 2094720.
  114. ^ Kamata T, Nishikawa M, Katagi M, Tsuchihashi H (2003). "Optimized glucuronide hydrolysis for the detection of psilocin in human urine samples". Journal of Chromatography B. 792 (2): 421–427. doi:10.1016/j.jchromb.2003.08.030. PMID 14581081.
  115. ^ Albers C, Köhler H, Lehr M, Brinkmann B, Beike J (2004). "Development of a psilocin immunoassay for serum and blood samples". International Journal of Legal Medicine. 118 (6): 326–331. doi:10.1007/s00414-004-0469-9. PMID 15526212. S2CID 11249439.
  116. ^ Lurie I, Li L (2009). "Use of high-temperature liquid chromatography with sub-2 μm particle C18 columns for the analysis of seized drugs". Journal of Liquid Chromatography & Related Technologies. 32 (17–20): 2615–2626. doi:10.1080/10826070903245516. S2CID 96753191. from the original on May 3, 2021. Retrieved August 24, 2020.
  117. ^ a b Guzmán G, Allen JW, Gartz J (2000). "A worldwide geographical distribution of the neurotropic fungi, an analysis and discussion" (PDF). Annali del Museo Civico di Rovereto: Sezione Archeologia, Storia, Scienze Naturali. 14: 189–280. (PDF) from the original on February 5, 2018. Retrieved October 19, 2021.
  118. ^ a b Guzmán G (2005). "Species diversity of the genus Psilocybe (Basidiomycotina, Agaricales, Strophariaceae) in the world mycobiota, with special attention to hallucinogenic properties". International Journal of Medicinal Mushrooms. 7 (1–2): 305–331. doi:10.1615/intjmedmushr.v7.i12.280.
  119. ^ Yong E (August 24, 2017). "How Mushrooms Became Magic". The Atlantic. from the original on March 16, 2018. Retrieved March 15, 2018.
  120. ^ Guzmán G (1983). The Genus Psilocybe: A Systematic Revision of the Known Species Including the History, Distribution, and Chemistry of the Hallucinogenic Species. Beihefte Zur Nova Hedwigia. Heft 74. Vaduz, Liechtenstein: J. Cramer. pp. 361–362. ISBN 978-3-7682-5474-8.
  121. ^ Saupe SG (1981). "Occurrence of psilocybin/psilocin in Pluteus salicinus (Plutaceae)". Mycologia. 73 (4): 871–874. doi:10.2307/3759505. JSTOR 3759505. from the original on March 10, 2017. Retrieved August 29, 2011.
  122. ^ Guzmán G, Allen JW, Gartz J (1998). (PDF). Annali del Museo Civico di Rovereto. 14: 207. Archived from the original (PDF) on June 26, 2010. Retrieved September 17, 2017.
  123. ^ Wurst M, Semerdžieva M, Vokoun J (1984). "Analysis of psychotropic compounds in fungi of the genus Psilocybe by reversed-phase high performance liquid chromatography". Journal of Chromatography A. 286: 229–235. doi:10.1016/S0021-9673(01)99190-3.
  124. ^ Kysilka R, Wurst M (1989). "High-performance liquid chromatographic determination of some psychotropic indole derivatives". Journal of Chromatography. 464 (2): 434–437. doi:10.1016/s0021-9673(00)94264-x. PMID 2722990.
  125. ^ a b Bigwood J, Beug MW (1982). "Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of Psilocybe cubensis (Earle) Singer". Journal of Ethnopharmacology. 5 (3): 287–291. doi:10.1016/0378-8741(82)90014-9. PMID 7201054.
  126. ^ Gartz J (1992). "New aspects of the occurrence, chemistry and cultivation of European hallucinogenic mushrooms". Supplemento Agli Annali dei Musei Civici di Rovereto Sezione Archeologica, Storia e Scienze Naturali. 8: 107–124.
  127. ^ Laussmann, Tim; Meier-Giebing, Sigrid (February 25, 2010). "Forensic analysis of hallucinogenic mushrooms and khat (Catha edulis Forsk) using cation-exchange liquid chromatography". Forensic Science International. 195 (1–3): 160–164. doi:10.1016/j.forsciint.2009.12.013. ISSN 1872-6283. PMID 20047807.
  128. ^ "Drug profiles: Hallucinogenic mushrooms". European Monitoring Centre for Drugs and Drug Addiction. September 19, 2011. from the original on November 27, 2011. Retrieved December 4, 2011.
  129. ^ Ohenoja E, Jokiranta J, Mäkinen T, Kaikkonen A, Airaksinen MM (1987). "The occurrence of psilocybin and psilocin in Finnish fungi". Journal of Natural Products. 50 (4): 741–744. doi:10.1021/np50052a030. PMID 3430170.
  130. ^ Gross ST (2000). (PDF). Journal of Forensic Sciences. 45 (3): 527–537. doi:10.1520/JFS14725J. PMID 10855955. S2CID 38006957. Archived from the original (PDF) on November 16, 2020.
  131. ^ Akers BP, Ruiz JF, Piper A, Ruck CA (2011). "A prehistoric mural in Spain depicting neurotropic Psilocybe mushrooms?". Economic Botany. 65 (2): 121–128. doi:10.1007/s12231-011-9152-5. S2CID 3955222.
  132. ^ Samorini, Giorgio (1992). "The oldest representations of hallucinogenic mushrooms in the world (Sahara Desert, 9000-7000 BP)". Integration. Zeitschrift für geistbewegende Pflanzen und Kultur. 2/3: 69–65.[permanent dead link]
  133. ^ a b c d Marley G (2010). Chanterelle Dreams, Amanita Nightmares: The Love, Lore, and Mystique of Mushrooms. White River Junction, Vermont: Chelsea Green Publishing. ISBN 978-1603582148.
  134. ^ a b c d Hofmann A (2009). LSD, my problem child: reflections on sacred drugs, mysticism, and science. Santa Cruz, California: Multidisciplinary Association for Psychedelic Studies. ISBN 978-0979862229.
  135. ^ Nyberg H (1992). "Religious use of hallucinogenic fungi: A comparison between Siberian and Mesoamerican Cultures". Karstenia. 32 (2): 71–80. doi:10.29203/ka.1992.294.
  136. ^ Wasson RG (1968). Soma: Divine Mushroom of Immortality. Harcourt Brace Jovanovick. p. 161. ISBN 978-0-88316-517-1.
  137. ^ a b Gartz J (1997). Magic Mushrooms Around the World. Los Angeles, California: LIS Publications. ISBN 978-0-9653399-0-2.
  138. ^ Wasson RG (May 13, 1957). "Seeking the magic mushroom". Life. pp. 101–120. ISSN 0024-3019. from the original on April 3, 2017. Retrieved February 27, 2016.
  139. ^ Heim R (1957). "Notes préliminaires sur les agarics hallucinogènes du Mexique" [Preliminary notes on the hallucination-producing agarics of Mexico]. Revue de Mycologie (in French). 22 (1): 58–79.
  140. ^ Leary T, Metzner R, Presnell M, Weil G, Schwitzgebel R, Kinne S (1965). "A new behavior change program using psilocybin". Psychotherapy: Theory, Research & Practice. 2 (2): 61–72. doi:10.1037/h0088612.
  141. ^ Johnson MW, Richards WA, Griffiths RR (2008). (PDF). Journal of Psychopharmacology. 22 (6): 603–620. doi:10.1177/0269881108093587. PMC 3056407. PMID 18593734. Archived from the original (PDF) on November 20, 2017. Retrieved November 20, 2017.
  142. ^ "The War on Drugs turns 50 today. It's time to make peace". The Washington Post. Retrieved August 8, 2023.
  143. ^ Griffiths RR, Grob CS (2010). (PDF). Scientific American. 303 (6): 77–79. Bibcode:2010SciAm.303f..76G. doi:10.1038/scientificamerican1210-76. Archived from the original (PDF) on October 3, 2011. Retrieved July 25, 2011.
  144. ^ a b Ott J (1993). Pharmacotheon: Entheogenic Drugs, their Plant Sources and History. Kennewick, Washington: Natural Products Company. ISBN 978-0-9614234-3-8.
  145. ^ Oeric OT, Os ON (1991). Psilocybin: Magic Mushroom Grower's Guide (2nd ed.). San Francisco, California: Quick American Archives. ISBN 978-0-932551-06-1.
  146. ^ San Antonio JP (1971). "A laboratory method to obtain fruit from cased grain spawn of the cultivated mushroom, Agaricus bisporus". Mycologia. 63 (1): 16–21. doi:10.2307/3757680. JSTOR 3757680. PMID 5102274. from the original on September 23, 2015. Retrieved September 7, 2011.
  147. ^ Keim B (July 1, 2008). "Psilocybin study hints at rebirth of hallucinogen research". Wired.com. from the original on August 3, 2011. Retrieved August 8, 2011.
  148. ^ Miller G (July 1, 2008). "A very memorable trip". sciencemag.org. from the original on August 13, 2018. Retrieved August 8, 2011.
  149. ^ (PDF). International Narcotics Control Board. August 2003. Archived from the original (PDF) on December 5, 2005. Retrieved June 25, 2007.
  150. ^ Griffiths & Grob, Roland R. & Charles S. (PDF). Scientific American. Archived from the original (PDF) on October 3, 2011. Retrieved March 22, 2013.
  151. ^ Szalavitz, Maia (June 16, 2011). "'Magic Mushrooms' Can Improve Psychological Health Long Term". Time. Retrieved March 22, 2013.
  152. ^ Griffiths, Roland R. (2011). "Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects". Psychopharmacology. 218 (4): 649–665. doi:10.1007/s00213-011-2358-5. PMC 3308357. PMID 21674151.
  153. ^ Jerome, Lisa. (PDF). MAPS. Archived from the original (PDF) on March 19, 2013. Retrieved March 22, 2013.
  154. ^ Schaepe, Herbert (September 13, 2001). "UN's INCB Psilocybin Mushroom Policy". Erowid.org. Retrieved January 7, 2012. As you are aware, mushrooms containing the above substances are collected and used for their hallucinogenic effects. As a matter of international law, no plants (natural material) containing psilocin and psilocybin are at present controlled under the Convention on Psychotropic Substances of 1971. Consequently, preparations made of these plants are not under international control and, therefore, not subject of the articles of the 1971 Convention [emphasis added]. Criminal cases are decided with reference to domestic law, which may otherwise provide for controls over mushrooms containing psilocine and psilocybin. As the Board can only speak as to the contours of the international drug conventions, I am unable to provide an opinion on the litigation in question. (Letter from Secretary of the UN International Narcotics Control Board to the Dutch Ministry of Health)
  155. ^ Hardon A, van Schipstal I, Berning M, Mishra S, Murray H, Mandler T, Kamps D, Hymans TD (December 2020). "Caring for "Hassle-Free Highs" in Amsterdam". Anthropology and Humanism. 45 (2): 212–22. doi:10.1111/anhu.12298. S2CID 228997721.
  156. ^ a b Pollan, M (2018). Como mudar sua mente [How to kill your mind] (in Portuguese). Editora Intrinseca. ISBN 9788551004173.
  157. ^ Shipley M (November 2015). Psychedelic mysticism: Transforming consciousness, religious experiences, and voluntary peasants in postwar America. Lexington Books. ISBN 978-1-4985-0910-7.
  158. ^ Lu, Donna; writer, Donna Lu Science (June 30, 2023). "Australian psychiatrists can now prescribe MDMA and psilocybin: who can access them and how do they work?". The Guardian. ISSN 0261-3077. Retrieved July 18, 2023.
  159. ^ Submission to the Western Australian Inquiry Into Alternative Approaches to Reducing Illicit Drug Use and Its Effects on the Community (PDF) (Report). Australian Psychedelic Society Inc. January 30, 2019. (PDF) from the original on August 23, 2021. Retrieved August 23, 2021.
  160. ^ Johansen PØ, Krebs TS (March 2015). "Psychedelics not linked to mental health problems or suicidal behavior: a population study". Journal of Psychopharmacology. 29 (3): 270–9. doi:10.1177/0269881114568039. PMID 25744618. S2CID 2025731.
  161. ^ Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE (November 2018). "The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act". Neuropharmacology. 142: 143–166. doi:10.1016/j.neuropharm.2018.05.012. PMC 6791528. PMID 29753748.
  162. ^ Rodd R (September 2018). "It's all you! Australian ayahuasca drinking, spiritual development, and immunitary individualism". Critique of Anthropology. 38 (3): 325–45. doi:10.1177/0308275X18775818. S2CID 149858755.
  163. ^ Bone E (2011). Mycophilia: Revelations from the Weird World of Mushrooms. New York, New York: Rodale. pp. 257–258. ISBN 978-1-60529-407-0. from the original on April 4, 2017. Retrieved February 27, 2016.
  164. ^ European Monitoring Centre for Drugs and Drug Addiction (November 2011). Annual report 2011: the state of the drugs problem in Europe (PDF) (Report). Luxembourg: Publications Office of the European Union. doi:10.2810/44330. ISBN 978-92-9168-470-0. (PDF) from the original on December 3, 2011. Retrieved December 4, 2011.
  165. ^ Guzmán G (2008). "Hallucinogenic mushrooms in Mexico: an overview". Economic Botany. 62 (3): 404–412. doi:10.1007/s12231-008-9033-8. S2CID 22085876.
  166. ^ Wark C, Galliher JF (2009). "Timothy Leary, Richard Alpert (Ram Dass) and the changing definition of psilocybin". The International Journal on Drug Policy. 21 (3): 234–239. doi:10.1016/j.drugpo.2009.08.004. PMID 19744846.
  167. ^ Goel, Dev B.; Zilate, Sarju (2022). "Potential Therapeutic Effects of Psilocybin: A Systematic Review". Cureus. 14 (10): e30214. doi:10.7759/cureus.30214. PMC 9650681. PMID 36381758.
  168. ^ Dos Santos RG, Osório FL, Crippa JA, Riba J, Zuardi AW, Hallak JE (June 2016). "Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years". Therapeutic Advances in Psychopharmacology. 6 (3): 193–213. doi:10.1177/2045125316638008. PMC 4910400. PMID 27354908.
  169. ^ Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. (December 2016). "Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial". Journal of Psychopharmacology. 30 (12): 1165–1180. doi:10.1177/0269881116675512. PMC 5367551. PMID 27909164.
  170. ^ "COMPASS Pathways Receives FDA Breakthrough Therapy Designation for Psilocybin Therapy for Treatment-resistant Depression". Compass Pathways. from the original on December 4, 2018. Retrieved December 3, 2018.
  171. ^ Richard Staines (December 2, 2019). "FDA tags psilocybin drug as clinical depression Breakthrough Therapy". Pharmaphorum. from the original on September 7, 2021. Retrieved September 7, 2021.
  172. ^ Więckiewicz G, Stokłosa I, Piegza M, Gorczyca P, Pudlo R (August 2021). "Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review". Pharmaceuticals. 14 (8): 793. doi:10.3390/ph14080793. PMC 8399008. PMID 34451890.

External links Edit

  • (Usona Institute, Madison, Wisconsin, 2021)

September 26, 2023
psilocybin, naturally, occurring, psychedelic, prodrug, compound, produced, more, than, species, fungi, most, potent, members, genus, psilocybe, such, azurescens, semilanceata, cyanescens, psilocybin, also, been, isolated, from, about, dozen, other, genera, it. Psilocybin a ˌ s aɪ l e ˈ s aɪ b ɪ n sy le SY bin ˌ s ɪ l is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi The most potent are members of genus Psilocybe such as P azurescens P semilanceata and P cyanescens but psilocybin has also been isolated from about a dozen other genera Psilocybin is itself biologically inactive but is quickly converted by the body to psilocin which has mind altering effects similar in some aspects to those of lysergic acid diethylamide LSD mescaline and dimethyltryptamine DMT In general the effects include euphoria visual and mental hallucinations changes in perception distorted sense of time and perceived spiritual experiences It can also cause adverse reactions such as nausea and panic attacks Psilocybin NamesPreferred IUPAC name 3 2 Dimethylamino ethyl 1H indol 4 yl dihydrogen phosphateIdentifiersCAS Number 520 52 5 Y3D model JSmol Interactive imageBeilstein Reference 273158ChEBI CHEBI 8614 YChEMBL ChEMBL194378 YChemSpider 10178 YECHA InfoCard 100 007 542EC Number 208 294 4KEGG C07576 YMeSH PsilocybinePubChem CID 10624RTECS number NM3150000UNII 2RV7212BP0 YCompTox Dashboard EPA DTXSID0048898InChI InChI 1S C12H17N2O4P c1 14 2 7 6 9 8 13 10 4 3 5 11 12 9 10 18 19 15 16 17 h3 5 8 13H 6 7H2 1 2H3 H2 15 16 17 YKey QVDSEJDULKLHCG UHFFFAOYSA N YInChI 1 C12H17N2O4P c1 14 2 7 6 9 8 13 10 4 3 5 11 12 9 10 18 19 15 16 17 h3 5 8 13H 6 7H2 1 2H3 H2 15 16 17 SMILES CN C CCC1 CNC2 C1C CC C2 OP O O OPharmacologyDependence liability LowRoutes ofadministration Oral intravenousPharmacokinetics Metabolism HepaticBiological half life Oral 163 64 minIntravenous 74 1 19 6 min 1 Excretion RenalLegal status AU S9 S8 Controlled Drug BR Class F2 Prohibited psychotropics 2 CA Schedule III UK Class A US Schedule IPropertiesChemical formula C 12H 17N 2O 4PMolar mass 284 252 g mol 1Melting point 220 228 C 428 442 F 3 Solubility in water SolubleSolubility Soluble in boiling methanol and water slightly soluble in ethanol insoluble in chloroform benzene 4 HazardsLethal dose or concentration LD LC LD50 median dose 285 mg kg mouse i v 280 mg kg rat i v 12 5 mg kg rabbit i v 3 Except where otherwise noted data are given for materials in their standard state at 25 C 77 F 100 kPa Y verify what is Y N Infobox references Imagery found on cave paintings and rock art of modern day Spain and Algeria suggests that human use of psilocybin mushrooms predates recorded history citation needed In Mesoamerica the mushrooms had long been consumed in spiritual and divinatory ceremonies before Spanish chroniclers first documented their use in the sixteenth century In 1958 the Swiss chemist Albert Hofmann isolated psilocybin and psilocin from the mushroom Psilocybe mexicana Hofmann s employer Sandoz marketed and sold pure psilocybin to physicians and clinicians worldwide for use in psychedelic therapy Although the increasingly restrictive drug laws of the 1960s and the 1970s curbed scientific research into the effects of psilocybin and other hallucinogens its popularity as an entheogen spirituality enhancing agent grew in the next decade owing largely to the increased availability of information on how to cultivate psilocybin mushrooms The intensity and duration of the effects of psilocybin are variable depending on species or cultivar of mushrooms dosage individual physiology and set and setting as was shown in experiments led by Timothy Leary at Harvard University in the early 1960s Once ingested psilocybin is rapidly metabolized to psilocin which then acts on serotonin receptors in the brain The mind altering effects of psilocybin typically last from two to six hours although to individuals under the influence of psilocybin the effects may seem to last much longer since the drug can distort the perception of time Possession of psilocybin containing mushrooms has been outlawed in most countries and psilocybin has been classified as a Schedule I controlled substance under the 1971 United Nations Convention on Psychotropic Substances Contents 1 Effects 1 1 Physical effects 1 2 Perceptual distortions 1 3 Group perceptions 2 Mystical experiences 2 1 Available forms 3 Adverse effects 3 1 Toxicity 3 2 Psychiatric 3 3 Tolerance and dependence 4 Chemistry 4 1 Physical properties 4 2 Laboratory synthesis 4 3 Biosynthesis 5 Pharmacology 5 1 Pharmacodynamics 5 2 Pharmacokinetics 5 3 Analytical methods 6 Natural occurrence 7 History 7 1 Early 7 2 Modern 8 Society and culture 8 1 Legal status 8 1 1 Advocacy for tolerance 8 2 Usage 9 Current research 10 See also 11 Notes 12 References 12 1 Citations 13 External linksEffects Edit nbsp American psychologist and counterculture figure Timothy Leary conducted early experiments into the effects of psychedelic drugs including psilocybin 1989 photo The effects of psilocybin are highly variable and depend on the mindset and environment in which the user has the experience factors commonly referred to as set and setting In the early 1960s Timothy Leary and colleagues at Harvard University investigated the role of set and setting on the effects of psilocybin They administered the drug to 175 volunteers from various backgrounds in an environment intended to be similar to a comfortable living room 98 of the subjects were given questionnaires to assess their experiences and the contribution of background and situational factors Individuals who had experience with psilocybin prior to the study reported more pleasant experiences than those for whom the drug was novel Group size dosage preparation and expectancy were important determinants of the drug response In general those in groups of more than eight felt that the groups were less supportive and their experiences less pleasant Conversely smaller groups fewer than six were seen as more supportive and reported more positive reactions to the drug in those groups Leary and colleagues proposed that psilocybin heightens suggestibility making an individual more receptive to interpersonal interactions and environmental stimuli 6 These findings were affirmed in a later review by Jos ten Berge 1999 who concluded that dosage set and setting were fundamental factors in determining the outcome of experiments that tested the effects of psychedelic drugs on artists creativity 7 After ingesting psilocybin a wide range of subjective effects may be experienced feelings of disorientation lethargy giddiness euphoria joy and depression In one study 31 of volunteers given a high dose reported feelings of significant fear and 17 experienced transient paranoia 8 In studies at Johns Hopkins among those given a moderate dose but still enough to give a high probability of a profound and beneficial experience negative experiences were rare whereas one third of those given a high dose experienced anxiety or paranoia 9 10 Low doses can induce hallucinatory effects Closed eye hallucinations may occur where the affected individual sees multicolored geometric shapes and vivid imaginative sequences 11 Some individuals report synesthesia such as tactile sensations when viewing colors 12 175 At higher doses psilocybin can lead to intensification of affective responses enhanced ability for introspection regression to primitive and childlike thinking and activation of vivid memory traces with pronounced emotional undertones 13 Open eye visual hallucinations are common and may be very detailed although rarely confused with reality 11 A 2011 prospective study by Roland R Griffiths and colleagues suggests that a single high dosage of psilocybin can cause long term changes in the personality of its users About half of the study participants described as healthy spiritually active and many possessing postgraduate degrees showed an increase in the personality dimension of openness assessed using the Revised NEO Personality Inventory and this positive effect was apparent more than a year after the psilocybin session According to the study authors the finding is significant because no study has prospectively demonstrated personality change in healthy adults after an experimentally manipulated discrete event 14 A further study by Griffiths in 2017 found that doses of 20 to 30mg 70kg psilocybin inducing mystical type experiences brought more lasting changes to traits including altruism gratitude forgiveness and feeling close to others when they were combined with a regular meditation practice and an extensive spiritual practice support program 15 16 Although other researchers have described instances of psychedelic drug usage leading to new psychological understandings and personal insights 17 it is not known whether these experimental results can be generalized to larger populations 14 Physical effects Edit Common responses include pupil dilation 93 changes in heart rate 100 including increases 56 decreases 13 and variable responses 31 changes in blood pressure 84 including hypotension 34 hypertension 28 and general instability 22 changes in stretch reflex 86 including increases 80 and decreases 6 nausea 44 tremor 25 and dysmetria 16 inability to properly direct or limit motions b The temporary increases in blood pressure caused by the drug can be a risk factor for users with pre existing hypertension 11 These qualitative somatic effects caused by psilocybin have been corroborated by several early clinical studies 19 A 2005 magazine survey of clubgoers in the UK found that nausea or vomiting was experienced by over a quarter of those who had used psilocybin mushrooms in the last year although this effect is caused by the mushroom rather than psilocybin itself 8 In one study administration of gradually increasing dosages of psilocybin daily for 21 days had no measurable effect on electrolyte levels blood sugar levels or liver toxicity tests 1 Perceptual distortions Edit nbsp The ability of psilocybin to cause perceptual distortions is linked to its influence on the activity of the prefrontal cortexPsilocybin is known to strongly influence the subjective experience of the passage of time 20 Users often feel as if time is slowed down resulting in the perception that minutes appear to be hours or time is standing still 21 Studies have demonstrated that psilocybin significantly impairs subjects ability to gauge time intervals longer than 2 5 seconds impairs their ability to synchronize to inter beat intervals longer than 2 seconds and reduces their preferred tapping rate 21 22 These results are consistent with the drug s role in affecting prefrontal cortex activity 23 and the role that the prefrontal cortex is known to play in time perception 24 However the neurochemical basis of psilocybin s effects on the perception of time are not known with certainty 25 Users having a pleasant experience can feel a sense of connection to others nature and the universe other perceptions and emotions are also often intensified Users having an unpleasant experience a bad trip describe a reaction accompanied by fear other unpleasant feelings and occasionally by dangerous behavior In general the phrase bad trip is used to describe a reaction that is characterized primarily by fear or other unpleasant emotions not just transitory experience of such feelings A variety of factors may contribute to a psilocybin user experiencing a bad trip including tripping during an emotional or physical low or in a non supportive environment see set and setting Ingesting psilocybin in combination with other drugs including alcohol can also increase the likelihood of a bad trip 8 26 Other than the duration of the experience the effects of psilocybin are similar to comparable dosages of lysergic acid diethylamide LSD or mescaline However in the Psychedelics Encyclopedia author Peter Stafford noted The psilocybin experience seems to be warmer not as forceful and less isolating It tends to build connections between people who are generally much more in communication than when they use LSD 27 273 Group perceptions Edit Through further anthropological studies regarding personal insights 28 and the psycho social effects of psilocybin it can be seen in many traditional societies that powerful mind active substances such as psilocybin are regularly consumed ritually for therapeutic purposes or for transcending normal everyday reality 29 Positive effects that psilocybin has on individuals can be observed by taking on an anthropological approach and moving away from the Western bio medical society this is aided by the studies done by Leary 30 Within certain traditional societies where the use of psilocybin is frequent for shamanic healing rituals group collectives praise their guide healer and shaman for helping alleviate them of pains aches and hurt They do this through a group ritual practice where participants or just the guide ingests psilocybin to help extract any toxic psychic residues or sorcerous implants 29 found in one s body Group therapies using classic psychedelics are becoming more commonly used in the Western world in clinical practice This may continue to grow as long providing the evidence remains indicative of safety and efficacy 31 In social sense the group is shaped by their experiences surrounding psilocybin and how they view the plant collectively As mentioned in the anthropology article 29 the group partakes in a journey together thus adding to the spiritual social body where roles hierarchies and gender are subjectively understood 29 Mystical experiences Edit nbsp In their studies on the psilocybin experience Johns Hopkins researchers use peaceful music and a comfortable room to help ensure a comfortable setting and experienced guides to monitor and reassure the volunteersPsilocybin mushrooms have been and continue to be used in indigenous New World cultures in religious divinatory or spiritual contexts Reflecting the meaning of the word entheogen the god within the mushrooms are revered as powerful spiritual sacraments that provide access to sacred worlds Typically used in small group community settings they enhance group cohesion and reaffirm traditional values 32 Terence McKenna documented the worldwide practices of psilocybin mushroom usage as part of a cultural ethos relating to the Earth and mysteries of nature and suggested that mushrooms enhanced self awareness and a sense of contact with a Transcendent Other reflecting a deeper understanding of our connectedness with nature 33 Psychedelic drugs can induce states of consciousness that have lasting personal meaning and spiritual significance in individuals who are religious or spiritually inclined these states are called mystical experiences Some scholars have proposed that many of the qualities of a drug induced mystical experience are indistinguishable from mystical experiences achieved through non drug techniques such as meditation or holotropic breathwork 34 35 In the 1960s Walter Pahnke and colleagues systematically evaluated mystical experiences which they called mystical consciousness by categorizing their common features These categories according to Pahnke describe the core of a universal psychological experience free from culturally determined philosophical or theological interpretations and allow researchers to assess mystical experiences on a qualitative numerical scale 36 In the 1962 Marsh Chapel Experiment which was run by Pahnke at the Harvard Divinity School under the supervision of Timothy Leary 37 almost all of the graduate degree divinity student volunteers who received psilocybin reported profound religious experiences 38 One of the participants was religious scholar Huston Smith author of several textbooks on comparative religion he later described his experience as the most powerful cosmic homecoming I have ever experienced 39 In a 25 year followup to the experiment all of the subjects given psilocybin described their experience as having elements of a genuine mystical nature and characterized it as one of the high points of their spiritual life 40 13 Psychedelic researcher Rick Doblin considered the study partially flawed due to incorrect implementation of the double blind procedure and several imprecise questions in the mystical experience questionnaire Nevertheless he said that the study cast a considerable doubt on the assertion that mystical experiences catalyzed by drugs are in any way inferior to non drug mystical experiences in both their immediate content and long term effects 40 24 This sentiment was echoed by psychiatrist William A Richards who in a 2007 review stated psychedelic mushroom use may constitute one technology for evoking revelatory experiences that are similar if not identical to those that occur through so called spontaneous alterations of brain chemistry 41 A group of researchers from Johns Hopkins School of Medicine led by Roland Griffiths conducted a study to assess the immediate and long term psychological effects of the psilocybin experience using a modified version of the mystical experience questionnaire and a rigorous double blind procedure 42 When asked in an interview about the similarity of his work with Leary s Griffiths explained the difference We are conducting rigorous systematic research with psilocybin under carefully monitored conditions a route which Dr Leary abandoned in the early 1960s 43 The National Institute of Drug Abuse funded study published in 2006 has been praised by experts for the soundness of its experimental design c In the experiment 36 volunteers without prior experience with hallucinogens were given psilocybin and methylphenidate Ritalin in separate sessions the methylphenidate sessions served as a control and psychoactive placebo The degree of mystical experience was measured using a questionnaire developed by Ralph W Hood 44 61 of subjects reported a complete mystical experience after their psilocybin session while only 13 reported such an outcome after their experience with methylphenidate Two months after taking psilocybin 79 of the participants reported moderately to greatly increased life satisfaction and sense of well being About 36 of participants also had a strong to extreme experience of fear or dysphoria i e a bad trip at some point during the psilocybin session which was not reported by any subject during the methylphenidate session about one third of these 13 of the total reported that this dysphoria dominated the entire session These negative effects were reported to be easily managed by the researchers and did not have a lasting negative effect on the subject s sense of well being 45 A follow up study conducted 14 months after the original psilocybin session confirmed that participants continued to attribute deep personal meaning to the experience Almost one third of the subjects reported that the experience was the single most meaningful or spiritually significant event of their lives and over two thirds reported it among their five most spiritually significant events About two thirds indicated that the experience increased their sense of well being or life satisfaction 38 Even after 14 months those who reported mystical experiences scored on average 4 percentage points higher on the personality trait of Openness Intellect personality traits are normally stable across the lifespan for adults Likewise in a recent 2010 web based questionnaire study designed to investigate user perceptions of the benefits and harms of hallucinogenic drug use 60 of the 503 psilocybin users reported that their use of psilocybin had a long term positive impact on their sense of well being 8 46 While many recent studies have concluded that psilocybin can cause mystical type experiences having substantial and sustained personal meaning and spiritual significance not all the medical community agree Paul R McHugh formerly director of the Department of Psychiatry and Behavioral Science at Johns Hopkins responded as follows in a book review The unmentioned fact in The Harvard Psychedelic Club is that LSD psilocybin mescaline and the like produce not a higher consciousness but rather a particular kind of lower consciousness known well to psychiatrists and neurologists namely toxic delirium 47 Available forms Edit Although psilocybin may be prepared synthetically outside of the research setting it is not typically used in this form The psilocybin present in certain species of mushrooms can be ingested in several ways by consuming fresh or dried fruit bodies by preparing an herbal tea or by combining with other foods to mask the bitter taste 48 In rare cases people have injected mushroom extracts intravenously 8 Adverse effects EditMost of the comparatively few fatal incidents reported in the literature that are associated with psychedelic mushroom usage involve the simultaneous use of other drugs especially alcohol Probably the most common cause of hospital admissions resulting from psychedelic mushroom usage involves bad trips or panic reactions in which affected individuals become extremely anxious confused agitated or disoriented Accidents self injury or suicide attempts can result from serious cases of acute psychotic episodes 8 Although no studies have linked psilocybin with birth defects 49 it is recommended that pregnant women avoid its usage 50 Toxicity Edit Data are sparse but in the decade leading up to 2020 an increasing number of psilocybin mushroom overdoses were recorded Nonetheless the number of events requiring hospitalization remain rare and overdoses are generally mild and self limiting A review regarding the management of psychedelic overdoses suggested that psilocybin related overdose management should prioritize managing the immediate adverse effects such as anxiety and paranoia rather than specific pharmacological interventions as its physiological toxicity tends to be rather limited 51 One analysis of mushrooms used by people hospitalized from psilocybin poisoning found high concentrations of phenethylamine PEA which has also been detected in the urine of people who have used psilocybin mushrooms It is hypothesized that PEA may intensify the effect of psilocybin poisoning 51 In rats the median lethal dose LD50 when administered orally is 280 milligrams per kilogram mg kg approximately one and a half times that of caffeine When administered intravenously in rabbits psilocybin s LD50 is approximately 12 5 mg kg 52 Psilocybin comprises approximately 1 of the weight of Psilocybe cubensis mushrooms and so nearly 1 7 kilograms 3 7 lb of dried mushrooms or 17 kilograms 37 lb of fresh mushrooms would be required for a 60 kilogram 130 lb person to reach the 280 mg kg LD50 value of rats 8 Based on the results of animal studies the lethal dose of psilocybin has been extrapolated to be 6 grams 1000 times greater than the effective dose of 6 milligrams 53 The Registry of Toxic Effects of Chemical Substances assigns psilocybin a relatively high therapeutic index of 641 higher values correspond to a better safety profile for comparison the therapeutic indices of aspirin and nicotine are 199 and 21 respectively 54 The lethal dose from psilocybin toxicity alone is unknown and has rarely been documented as of 2011 update only two cases attributed to overdosing on hallucinogenic mushrooms without concurrent use of other drugs have been reported in the scientific literature and may involve other factors aside from psilocybin 8 d Psychiatric Edit Panic reactions can occur after consumption of psilocybin containing mushrooms especially if the ingestion is accidental or otherwise unexpected Reactions characterized by violent behavior suicidal thoughts 57 schizophrenia like psychosis 58 59 and convulsions 60 have been reported in the literature A 2005 survey conducted in the United Kingdom found that almost a quarter of those who had used psilocybin mushrooms in the past year had experienced a panic attack 8 failed verification Other adverse effects less frequently reported include paranoia confusion prolonged derealization disconnection from reality and mania 46 Psilocybin usage can temporarily induce a state of depersonalization disorder 61 Usage by those with schizophrenia can induce acute psychotic states requiring hospitalization 62 The similarity of psilocybin induced symptoms to those of schizophrenia has made the drug a useful research tool in behavioral and neuroimaging studies of this psychotic disorder 63 64 65 In both cases psychotic symptoms are thought to arise from a deficient gating of sensory and cognitive information in the brain that ultimately lead to cognitive fragmentation and psychosis 64 Flashbacks spontaneous recurrences of a previous psilocybin experience can occur long after having used psilocybin mushrooms Hallucinogen persisting perception disorder HPPD is characterized by a continual presence of visual disturbances similar to those generated by psychedelic substances Neither flashbacks nor HPPD are commonly associated with psilocybin usage 8 and correlations between HPPD and psychedelics are further obscured by polydrug use and other variables 66 Tolerance and dependence Edit nbsp Chart of dependence potential and effective dose lethal dose ratio of several psychoactive drugs 67 Tolerance to psilocybin builds and dissipates quickly ingesting psilocybin more than about once a week can lead to diminished effects Tolerance dissipates after a few days so doses can be spaced several days apart to avoid the effect 68 A cross tolerance can develop between psilocybin and the pharmacologically similar LSD 69 and between psilocybin and phenethylamines such as mescaline and DOM 70 Repeated use of psilocybin does not lead to physical dependence 1 A 2008 study concluded that based on US data from the period 2000 2002 adolescent onset defined here as ages 11 17 usage of hallucinogenic drugs including psilocybin did not increase the risk of drug dependence in adulthood this was in contrast to adolescent usage of cannabis cocaine inhalants anxiolytic medicines and stimulants all of which were associated with an excess risk of developing clinical features associated with drug dependence 71 Likewise a 2010 Dutch study ranked the relative harm of psilocybin mushrooms compared to a selection of 19 recreational drugs including alcohol cannabis cocaine ecstasy heroin and tobacco Psilocybin mushrooms were ranked as the illicit drug with the lowest harm 72 corroborating conclusions reached earlier by expert groups in the United Kingdom 73 Chemistry EditPhysical properties Edit Psilocybin is a naturally occurring substituted tryptamine that features an indole ring linked to an aminoethyl substituent It is structurally related to serotonin a monoamine neurotransmitter which is a derivative of the amino acid tryptophan Psilocybin is a member of the general class of tryptophan based compounds that originally functioned as antioxidants in earlier life forms before assuming more complex functions in multicellular organisms including humans 74 Other related indole containing psychedelic compounds include dimethyltryptamine found in many plant species and in trace amounts in some mammals and bufotenin found in the skin of certain amphibians especially the Colorado River toad 75 10 13 Psilocybin is a white crystalline solid that is soluble in water methanol and ethanol but insoluble in nonpolar organic solvents such as chloroform and petroleum ether 75 15 It has a melting point between 220 228 C 428 442 F 52 and an ammonia like taste 76 Its pKa values are estimated to be 1 3 and 6 5 for the two successive phosphate hydroxy groups and 10 4 for the dimethylamine nitrogen so it typically exists as a zwitterionic structure 76 There are two known crystalline polymorphs of psilocybin as well as reported hydrated phases 77 Psilocybin rapidly oxidizes upon exposure to light an important consideration when using it as an analytical standard 78 Laboratory synthesis Edit Albert Hofmann et al were the first team to synthesize psilocybin in 1958 Since that time various chemists have improved the methods for the laboratory synthesis and purification of psilocybin In particular Shirota et al reported a novel method in 2003 for the synthesis of psilocybin at the gram scale from 4 hydroxyindole that does not require chromatographic purification Fricke et al described an enzymatic pathway for the synthesis of psilocybin and psilocin publishing their results in 2017 Sherwood et al significantly improved upon Shirota s method producing at the kilogram scale while employing less expensive reagents publishing their results in 2020 79 Biosynthesis Edit nbsp Biosynthetic route previously thought to lead to psilocybin It has recently been shown that 4 hydroxylation and O phosphorylation immediately follow decarboxylation and neither dimethyltryptamine nor psilocin are intermediates although spontaneously generated psilocin can be converted back to psilocybin 80 Isotopic labeling experiments from the 1960s suggested that the biosynthesis of psilocybin was a four step process 81 decarboxylation of tryptophan to tryptamine N N dimethylation of tryptamine at the N9 position to dimethyltryptamine 4 hydroxylation of dimethyltryptamine to psilocin O phosphorylation of psilocin to psilocybinMore recent research has demonstrated that at least in P cubensis O phosphorylation is in fact the third step and that neither dimethyltryptamine nor psilocin are intermediates 80 The sequence of the intermediate steps has been shown to involve four enzymes PsiD PsiH PsiK and PsiM in P cubensis and P cyanescens although it is possible that the biosynthetic pathway differs between species 75 12 13 80 These enzymes are encoded in gene clusters in Psilocybe Panaeolus and Gymnopilus 82 Escherichia coli has been genetically modified to manufacture large amounts of psilocybin 83 Psilocybin can be produced de novo in GM yeast 84 85 Pharmacology EditPharmacodynamics Edit nbsp The neurotransmitter serotonin is structurally similar to psilocybinPsilocybin is a psychoplastogen 86 87 88 which refers to a compound capable of promoting rapid and sustained neuroplasticity Psilocybin is rapidly dephosphorylated in the body to psilocin which is an agonist for several serotonin receptors which are also known as 5 hydroxytryptamine 5 HT receptors In rats psilocin binds with high affinity to 5 HT2A receptors and low affinity to 5 HT1 receptors including 5 HT1A and 5 HT1D effects are also mediated via 5 HT2C receptors 1 The psychotomimetic psychosis mimicking effects of psilocin can be blocked in a dose dependent fashion by the 5 HT2A antagonist drug ketanserin 58 Various lines of evidence have shown that interactions with non 5 HT2 receptors also contribute to the subjective and behavioral effects of the drug 70 e For example psilocin indirectly increases the concentration of the neurotransmitter dopamine in the basal ganglia and some psychotomimetic symptoms of psilocin are reduced by haloperidol a non selective dopamine receptor antagonist Taken together these suggest that there may be an indirect dopaminergic contribution to psilocin s psychotomimetic effects 25 Psilocybin and psilocin have no affinity for dopamine receptor D2 unlike another common 5 HT receptor agonist lysergic acid diethylamide LSD 1 Psilocin antagonizes H1 receptors with moderate affinity compared to LSD which has a lower affinity 90 Serotonin receptors are located in numerous parts of the brain including the cerebral cortex and are involved in a wide range of functions including regulation of mood motivation body temperature appetite and libido 91 Psilocybin induces region dependent alterations in glutamate that may be associated with subjective experiences of ego dissolution 92 Pharmacokinetics Edit nbsp Psilocybin is converted in the liver to the pharmacologically active psilocin which is then either glucuronated to be excreted in the urine or further converted to various psilocin metabolitesThe effects of the drug begin 10 40 minutes after ingestion and last 2 6 hours depending on dose species and individual metabolism 93 36 41 The half life of psilocybin is 163 64 minutes when taken orally or 74 1 19 6 minutes when injected intravenously 1 Psilocybin is metabolized mostly in the liver As it becomes converted to psilocin it undergoes a first pass effect whereby its concentration is greatly reduced before it reaches the systemic circulation Psilocin is broken down by the enzyme monoamine oxidase to produce several metabolites that can circulate in the blood plasma including 4 hydroxyindole 3 acetaldehyde 4 hydroxytryptophol and 4 hydroxyindole 3 acetic acid 1 Some psilocin is not broken down by enzymes and instead forms a glucuronide this is a biochemical mechanism animals use to eliminate toxic substances by linking them with glucuronic acid which can then be excreted in the urine 94 95 Psilocin is glucuronated by the glucuronosyltransferase enzymes UGT1A9 in the liver and by UGT1A10 in the small intestine 96 Based on studies using animals about 50 of ingested psilocybin is absorbed through the stomach and intestine Within 24 hours about 65 of the absorbed psilocybin is excreted into the urine and a further 15 20 is excreted in the bile and feces Although most of the remaining drug is eliminated in this way within 8 hours it is still detectable in the urine after 7 days 97 Clinical studies show that psilocin concentrations in the plasma of adults average about 8 mg liter within 2 hours after ingestion of a single 15 mg oral psilocybin dose 98 psychological effects occur with a blood plasma concentration of 4 6 mg liter 1 Psilocybin is approximately 1 100 the potency of LSD on a weight per weight basis and the physiological effects last about half as long 12 171 Monoamine oxidase inhibitors MAOI have been known to prolong and enhance the effects of DMT and one study assumed that the effect on psilocybin would be similar since it is a structural analogue of DMT 99 Alcohol consumption may enhance the effects of psilocybin because acetaldehyde one of the primary breakdown metabolites of consumed alcohol reacts with biogenic amines present in the body to produce MAOIs related to tetrahydroisoquinoline and b carboline 8 Tobacco smokers may also experience more powerful effects with psilocybin 8 because tobacco smoke exposure decreases the activity of MAO in the brain and peripheral organs 100 Analytical methods Edit Several relatively simple chemical tests commercially available as reagent testing kits can be used to assess the presence of psilocybin in extracts prepared from mushrooms The drug reacts in the Marquis test to produce a yellow color and a green color in the Mandelin reagent 101 Neither of these tests however is specific for psilocybin for example the Marquis test will react with many classes of controlled drugs such as those containing primary amino groups and unsubstituted benzene rings including amphetamine and methamphetamine 102 Ehrlich s reagent and DMACA reagent are used as chemical sprays to detect the drug after thin layer chromatography 103 Many modern techniques of analytical chemistry have been used to quantify psilocybin levels in mushroom samples Although the earliest methods commonly used gas chromatography the high temperature required to vaporize the psilocybin sample prior to analysis causes it to spontaneously lose its phosphoryl group and become psilocin making it difficult to chemically discriminate between the two drugs In forensic toxicology techniques involving gas chromatography coupled to mass spectrometry GC MS are the most widely used due to their high sensitivity and ability to separate compounds in complex biological mixtures 104 These techniques include ion mobility spectrometry 105 capillary zone electrophoresis 106 ultraviolet spectroscopy 107 and infrared spectroscopy 108 High performance liquid chromatography HPLC is used with ultraviolet 78 fluorescence 109 electrochemical 110 and electrospray mass spectrometric detection methods 111 Various chromatographic methods have been developed to detect psilocin in body fluids the rapid emergency drug identification system REMEDi HS a drug screening method based on HPLC 112 HPLC with electrochemical detection 110 113 GC MS 94 112 and liquid chromatography coupled to mass spectrometry 114 Although the determination of psilocin levels in urine can be performed without sample clean up i e removing potential contaminants that make it difficult to accurately assess concentration the analysis in plasma or serum requires a preliminary extraction followed by derivatization of the extracts in the case of GC MS A specific immunoassay has also been developed to detect psilocin in whole blood samples 115 A 2009 publication reported using HPLC to quickly separate forensically important illicit drugs including psilocybin and psilocin which were identifiable within about half a minute of analysis time 116 These analytical techniques to determine psilocybin concentrations in body fluids are however not routinely available and not typically used in clinical settings 26 Natural occurrence EditMaximum reported psilocybin concentrations dry weight in 12 Psilocybe species 93 39 Species psilocybinP azurescens 1 78P serbica 1 34P semilanceata 0 98P baeocystis 0 85P cyanescens 0 85P tampanensis 0 68P cubensis 0 63P weilii 0 61P hoogshagenii 0 60P stuntzii 0 36P cyanofibrillosa 0 21P liniformans 0 16Psilocybin is present in varying concentrations in over 200 species of Basidiomycota mushrooms In a 2000 review on the worldwide distribution of hallucinogenic mushrooms Gaston Guzman and colleagues considered these to be distributed amongst the following genera Psilocybe 116 species Gymnopilus 14 Panaeolus 13 Copelandia 12 Hypholoma 6 Pluteus 6 Inocybe 6 Conocybe 4 Panaeolina 4 Gerronema 2 and Galerina 1 species 117 Guzman increased his estimate of the number of psilocybin containing Psilocybe to 144 species in a 2005 review The majority of these are found in Mexico 53 species with the remainder distributed in the United States and Canada 22 Europe 16 Asia 15 Africa 4 and Australia and associated islands 19 118 The diversity of psilocybin mushrooms is reported to have been increased by horizontal transfer of the psilocybin gene cluster between unrelated mushroom species 119 82 In general psilocybin containing species are dark spored gilled mushrooms that grow in meadows and woods of the subtropics and tropics usually in soils rich in humus and plant debris 75 5 Psilocybin mushrooms occur on all continents but the majority of species are found in subtropical humid forests 117 Psilocybe species commonly found in the tropics include P cubensis and P subcubensis P semilanceata considered by Guzman to be the world s most widely distributed psilocybin mushroom 120 is found in Europe North America Asia South America Australia and New Zealand but is entirely absent from Mexico 118 Although the presence or absence of psilocybin is not of much use as a chemotaxonomical marker at the familial level or higher it is used to classify taxa of lower taxonomic groups 121 nbsp Global distribution of over 100 psychoactive species of genus Psilocybe mushrooms 122 nbsp Psilocybin was first isolated from Psilocybe mexicana nbsp P semilanceata is common in Europe Canada and the United States Both the caps and the stems contain psychoactive compounds although the caps consistently contain more The spores of these mushrooms do not contain psilocybin or psilocin 105 123 124 The total potency varies greatly between species and even between specimens of a species collected or grown from the same strain 125 Because most psilocybin biosynthesis occurs early in the formation of fruit bodies or sclerotia younger smaller mushrooms tend to have a higher concentration of the drug than larger mature mushrooms 126 In general the psilocybin content of mushrooms is quite variable ranging from almost nothing to 2 5 of the dry weight 127 27 248 and depends on species strain growth and drying conditions and mushroom size 93 36 41 52 Cultivated mushrooms have less variability in psilocybin content than wild mushrooms 128 The drug is more stable in dried than fresh mushrooms dried mushrooms retain their potency for months or even years 93 51 5 while mushrooms stored fresh for four weeks contain only traces of the original psilocybin 8 The psilocybin contents of dried herbarium specimens of Psilocybe semilanceata in one study were shown to decrease with the increasing age of the sample collections dated 11 33 or 118 years old contained 0 84 0 67 and 0 014 all dry weight respectively 129 Mature mycelia contain some psilocybin while young mycelia recently germinated from spores lack appreciable amounts 130 Many species of mushrooms containing psilocybin also contain lesser amounts of the analog compounds baeocystin and norbaeocystin 93 38 chemicals thought to be biogenic precursors 12 170 Although most species of psilocybin containing mushrooms bruise blue when handled or damaged due to the oxidization of phenolic compounds this reaction is not a definitive method of identification or determining a mushroom s potency 125 93 56 58 History EditEarly Edit nbsp Mayan mushroom stones of GuatemalaThere is evidence to suggest that psychoactive mushrooms have been used by humans in religious ceremonies for thousands of years 6 000 year old pictographs discovered near the Spanish town of Villar del Humo illustrate several mushrooms that have been tentatively identified as Psilocybe hispanica a hallucinogenic species native to the area 131 The rock art was also discovered in Tassili Algeria and is believed to depict psychedelic mushrooms and the transformation of the user under their influence The paintings are said to date back to 9000 7000 BC 132 Archaeological artifacts from Mexico as well as the so called Mayan mushroom stones of Guatemala have also been interpreted by some scholars as evidence for ritual and ceremonial usage of psychoactive mushrooms in the Mayan and Aztec cultures of Mesoamerica 93 11 In Nahuatl the language of the Aztecs the mushrooms were called teonanacatl or God s flesh Following the arrival of Spanish explorers to the New World in the sixteenth century chroniclers reported the use of mushrooms by the natives for ceremonial and religious purposes According to the Dominican friar Diego Duran in The History of the Indies of New Spain published c 1581 mushrooms were eaten in festivities conducted on the occasion of the accession to the throne of Aztec emperor Moctezuma II in 1502 The Franciscan friar Bernardino de Sahagun wrote of witnessing mushroom usage in his Florentine Codex published 1545 1590 133 164 and described how some merchants would celebrate upon returning from a successful business trip by consuming mushrooms to evoke revelatory visions 134 118 After the defeat of the Aztecs the Spanish forbade traditional religious practices and rituals that they considered pagan idolatry including ceremonial mushroom use For the next four centuries the Indians of Mesoamerica hid their use of entheogens from the Spanish authorities 133 165 Although dozens of species of psychedelic mushrooms are found in Europe there is little documented usage of these species in Old World history besides the use of Amanita muscaria among Siberian peoples 135 136 The few existing historical accounts about psilocybin mushrooms typically lack sufficient information to allow species identification and usually refer to the nature of their effects For example Flemish botanist Carolus Clusius 1526 1609 described the bolond gomba crazy mushroom used in rural Hungary to prepare love potions English botanist John Parkinson included details about a foolish mushroom in his 1640 herbal Theatricum Botanicum 137 10 12 The first reliably documented report of intoxication with Psilocybe semilanceata Europe s most common and widespread psychedelic mushroom involved a British family in 1799 who prepared a meal with mushrooms they had picked in London s Green Park 137 16 Modern Edit nbsp Albert Hofmann shown here in 1993 purified psilocybin and psilocin from Psilocybe mexicana in the late 1950s nbsp The increasing availability of information on growing techniques made it possible for amateurs to grow psilocybin mushrooms Psilocybe cubensis pictured without access to laboratory equipmentAmerican banker and amateur ethnomycologist R Gordon Wasson and his wife Valentina P Wasson a physician studied the ritual use of psychoactive mushrooms by the native population in the Mazatec village Huautla de Jimenez Mexico In 1957 Wasson described the psychedelic visions that he experienced during these rituals in Seeking the Magic Mushroom an article published in the popular American weekly Life magazine 138 Later the same year they were accompanied on a follow up expedition by French mycologist Roger Heim who identified several of the mushrooms as Psilocybe species 139 Heim cultivated the mushrooms in France and sent samples for analysis to Albert Hofmann a chemist employed by the Swiss pharmaceutical company Sandoz now Novartis Hofmann who had synthesized lysergic acid diethylamide LSD in 1938 led a research group that isolated and identified the psychoactive alkaloids psilocybin and psilocin from Psilocybe mexicana publishing their results in 1958 134 128 The team was aided in the discovery process by Hofmann s willingness to ingest mushroom extracts to help verify the presence of the active compounds 134 126 127 Next Hofmann s team synthesized several structural analogs of these compounds to examine how these structural changes would affect psychoactivity This research led to the development of ethocybin and CZ 74 Because the physiological effects of these compounds last only about three and a half hours about half as long as psilocybin they proved more manageable than the latter for use in psycholytic therapy 27 237 Sandoz also marketed and sold pure psilocybin under the name Indocybin to clinicians and researchers worldwide 133 166 There were no reports of serious complications when psilocybin was used in this way 1 In the early 1960s Harvard University became a testing ground for psilocybin through the efforts of Timothy Leary and his associates Ralph Metzner and Richard Alpert who later changed his name to Ram Dass Leary obtained synthesized psilocybin from Hofmann through Sandoz Pharmaceuticals Some studies such as the Concord Prison Experiment suggested promising results using psilocybin in clinical psychiatry 6 140 According to a 2008 review of safety guidelines in human hallucinogenic research however Leary and Alpert s well publicized termination from Harvard and later advocacy of hallucinogen use further undermined an objective scientific approach to studying these compounds 141 In response to concerns about the increase in unauthorized use of psychedelic drugs by the general public psilocybin and other hallucinogenic drugs suffered negative press and faced increasingly restrictive laws In the United States laws were passed in 1966 that prohibited the production trade or ingestion of hallucinogenic drugs Sandoz stopped producing LSD and psilocybin the same year 97 In 1970 Congress passed The Federal Comprehensive Drug Abuse Prevention and Control Act that made LSD peyote psilocybin and other hallucinogens illegal to use for any and all purposes including scientific research 142 United States politicians agenda against LSD usage had swept psilocybin along with it into the Schedule I category of illicit drugs Such restrictions on the use of these drugs in human research made funding for such projects difficult to obtain globally and scientists who worked with psychedelic drugs faced being professionally marginalized 143 Although Hofmann tested these compounds on himself never advocated their legalization or medical use In his 1979 book LSD mein Sorgenkind LSD my problem child Hofmann described the problematic use of these hallucinogens as inebriants 134 79 116 Despite the legal restrictions on psilocybin use the 1970s witnessed the emergence of psilocybin as the entheogen of choice 144 276 This was due in large part to a wide dissemination of information on the topic which included works such as those by author Carlos Castaneda and several books that taught the technique of growing psilocybin mushrooms One of the most popular of this latter group was published in 1976 under the pseudonyms O T Oss and O N Oeric by Jeremy Bigwood Dennis J McKenna K Harrison McKenna and Terence McKenna entitled Psilocybin Magic Mushroom Grower s Guide Over 100 000 copies were sold by 1981 145 As ethnobiologist Jonathan Ott explains These authors adapted San Antonio s technique for producing edible mushrooms by casing mycelial cultures on a rye grain substrate San Antonio 1971 to the production of Psilocybe Stropharia cubensis The new technique involved the use of ordinary kitchen implements and for the first time the layperson was able to produce a potent entheogen in his own home without access to sophisticated technology equipment or chemical supplies 144 290 San Antonio s technique describes a method to grow the common edible mushroom Agaricus bisporus 146 Because of a lack of clarity about laws about psilocybin mushrooms specifically in the form of sclerotia also known as truffles European retailers in the late 1990s and early 2000s commercialized and marketed them in smartshops in the Netherlands and the UK and online Several websites f emerged that have contributed to the accessibility of information on description use effects and exchange of experiences among users Since 2001 six EU countries have tightened their legislation on psilocybin mushrooms in response to concerns about their prevalence and increasing usage 48 In the 1990s hallucinogens and their effects on human consciousness were again the subject of scientific study particularly in Europe Advances in neuropharmacology and neuropsychology and the availability of brain imaging techniques have provided impetus for using drugs like psilocybin to probe the neural underpinnings of psychotic symptom formation including ego disorders and hallucinations 13 Recent studies in the United States have attracted attention from the popular press and thrust psilocybin back into the limelight 147 148 Society and culture EditLegal status Edit Further information Legal status of psilocybin mushrooms and Psilocybin decriminalization in the United States This section is an excerpt from Legal status of psilocybin mushrooms edit The legal status of unauthorised actions with psilocybin mushrooms varies worldwide Psilocybin and psilocin are listed as Schedule I drugs under the United Nations 1971 Convention on Psychotropic Substances 149 Schedule I drugs are defined as drugs with a high potential for abuse or drugs that have no recognized medical uses However psilocybin mushrooms have had numerous medicinal 150 151 152 and religious uses in dozens of cultures throughout history and have a significantly lower potential for abuse than other Schedule I drugs 153 Psilocybin mushrooms are not regulated by UN treaties 154 Many countries however have some level of regulation or prohibition of psilocybin mushrooms for example the US Psychotropic Substances Act the UK Misuse of Drugs Act 1971 and the Canadian Controlled Drugs and Substances Act In some jurisdictions Psilocybe spores are legal to sell and possess because they contain neither psilocybin nor psilocin citation needed In other jurisdictions they are banned because they are items that are used in drug manufacture A few jurisdictions such as the US states of California Georgia and Idaho have specifically prohibited the sale and possession of psilocybin mushroom spores Cultivation of psilocybin mushrooms is considered drug manufacture in most jurisdictions and is often severely penalized though some countries and one US state New Mexico has ruled that growing psilocybin mushrooms does not qualify as manufacturing a controlled substance citation needed Advocacy for tolerance Edit Despite being illegal in many typically Western countries such as the UK Australia and some US states less conservative governments opt to nurture the legal use of psilocybin and other psychedelic drugs In Amsterdam Netherlands authorities provide education and promotion on the safe use of psychedelic drugs such as psilocybin in an aim to reduce public harm 155 Similarly religious groups like America s Uniao do Vegetal UDV 156 use psychedelics in traditional ceremonies 157 From 1st July 2023 the Australian medicines regulator has permitted psychiatrists to prescribe psilocybin for the therapeutic treatment of post traumatic stress disorder 158 Advocates for legalization argue there is a lack of evidence of harm 159 160 and potential use in treating certain mental health conditions Research is difficult to conduct because of the legal status of psychoactive substances 161 Advocates for legalization also promote the utility of ego dissolution 156 and argue bans are cultural discrimination against traditional users 162 Usage Edit nbsp Dried Psilocybe mushrooms showing the characteristic blue bruising on the stemsA 2009 national survey of drug use by the US Department of Health and Human Services concluded that the number of first time psilocybin mushroom users in the United States was roughly equivalent to the number of first time users of cannabis 163 In European countries the lifetime prevalence estimates of psychedelic mushroom usage among young adults 15 34 years range from 0 3 to 14 1 164 In modern Mexico traditional ceremonial use survives among several indigenous groups including the Nahuas the Matlatzinca the Totonacs the Mazatecs Mixes Zapotecs and the Chatino Although hallucinogenic Psilocybe species are abundant in low lying areas of Mexico most ceremonial use takes places in mountainous areas of elevations greater than 1 500 meters 4 900 ft Guzman suggests this is a vestige of Spanish colonial influence from several hundred years earlier when mushroom use was persecuted by the Catholic Church 165 Current research EditSee also Psychedelic therapy Psilocybin has been a subject of clinical research since the early 1960s when the Harvard Psilocybin Project evaluated the potential value of psilocybin as a treatment for certain personality disorders 166 Beginning in the 2000s psilocybin has been investigated for its possible role in the treatment of nicotine dependence alcohol dependence obsessive compulsive disorder OCD cluster headache cancer related existential distress 79 167 anxiety disorders and certain mood disorders 133 179 81 168 169 In 2018 the United States Food and Drug Administration FDA granted breakthrough therapy designation for psilocybin assisted therapy for treatment resistant depression 170 171 A systematic review published in 2021 found that the use of psilocybin as a pharmaceutical substance was associated with reduced intensity of depression symptoms 172 The role of psilocybin as a possible psychoplastogen is also being examined 86 87 88 See also Edit nbsp Fungi portalList of entheogens O Acetylpsilocin Psychedelic microdosing Psychoactive plant Soma drink Notes Edit Synonyms and alternate spellings include 4 PO DMT PO phosphate DMT dimethyltryptamine psilocybine psilocibin psilocybinum psilotsibin psilocin phosphate ester and indocybin 5 Percentages are derived from a non blind clinical study of 30 individuals who were given a dosage of 8 12 milligrams of psilocybin from Passie 2002 1 citing Quentin 1960 18 The academic communities approval for the methodology employed is exemplified by the quartet of commentaries published in the journal Psychopharmacology titled Commentary on Psilocybin can occasion mystical type experiences having substantial and sustained personal meaning and spiritual experience by Griffiths et al by HD Kleber pp 291 292 DE Nichols pp 284 286 CR Schuster pp 289 290 and SH Snyder pp 287 288 One of the reported fatalities that of a 22 year old French man who died in 1993 55 was later challenged in the literature by Jochen Gartz and colleagues who concluded the few reported data concerning the victim are insufficient to exclude other possible causes of the fatality 56 Subjective effects are feelings perceptions and moods personally experienced by an individual they are often assessed using methods of self report including questionnaires Behavioral effects in contrast can be observed directly 89 The EMCDDA lists the general purpose websites Erowid Lycaeum Mycotopia The Shroomery MushroomJohn and The Entheogen Review Regional sites focusing on hallucinogenic mushrooms listed were Copenhagen Mushroom Link Denmark Champis France Daath Hungary Delysid Spain Enteogeneos Portugal Kouzelne houbicky Czech Republic Norshroom Norway Planetahongo Spain Svampinfo Sweden and Taikasieniforum Finland It also listed Magic Mushrooms net The report detailed several additional sites selling spore prints in 2006 but noted that many of these had ceased operation References EditCitations Edit a b c d e f g h i j Passie T Seifert J Schneider U Emrich HM 2002 The pharmacology of psilocybin Addiction Biology 7 4 357 364 doi 10 1080 1355621021000005937 PMID 14578010 S2CID 12656091 Anvisa July 24 2023 RDC Nº 804 Listas de Substancias Entorpecentes Psicotropicas Precursoras e Outras sob Controle Especial Collegiate Board Resolution No 804 Lists of Narcotic Psychotropic Precursor and Other Substances under Special Control in Brazilian Portuguese Diario Oficial da Uniao published July 25 2023 Archived from the original on August 27 2023 Retrieved August 27 2023 a b Merck Index 11th Edition 7942 Psilocybine PubChem US National Library of Medicine August 27 2022 Retrieved August 29 2022 Psilocybine Compound Summary PubChem National Library of Medicine Archived from the original on September 25 2012 Retrieved December 4 2011 a b Leary T Litwin GH Metzner R 1963 Reactions to psilocybin administered in a supportive environment Journal of Nervous and Mental Disease 137 6 561 573 doi 10 1097 00005053 196312000 00007 PMID 14087676 S2CID 39777572 Berge JT 1999 Breakdown or breakthrough A history of European research into drugs and creativity Journal of Creative Behavior 33 4 257 276 doi 10 1002 j 2162 6057 1999 tb01406 x ISSN 0022 0175 a b c d e f g h i j k l m van Amsterdam J Opperhuizen A van den Brink W 2011 Harm potential of magic mushroom use a review PDF Regulatory Toxicology and Pharmacology 59 3 423 429 doi 10 1016 j yrtph 2011 01 006 PMID 21256914 Archived from the original PDF on January 9 2015 Hallucinogenic Drug Psilocybin Eases Existential Anxiety in People With Life Threatening Cancer Johns Hopkins December 1 2016 Archived from the original on April 7 2021 Retrieved April 9 2019 Griffiths RR Johnson MW Richards WA Richards BD McCann U Jesse R June 15 2011 Psilocybin occasioned mystical type experiences Immediate and persisting dose related effects Johns Hopkins 218 4 649 665 doi 10 1007 s00213 011 2358 5 PMC 3308357 PMID 21674151 a b c Hasler F Grimberg U Benz MA Huber T Vollenweider FX 2004 Acute psychological and physiological effects of psilocybin in healthy humans a double blind placebo controlled dose effect study PDF Psychopharmacology 172 2 145 156 doi 10 1007 s00213 003 1640 6 PMID 14615876 S2CID 15263504 Archived PDF from the original on April 18 2020 Retrieved April 10 2019 a b c Ballesteros S Ramon MF Iturralde MJ Martinez Arrieta R 2006 Natural sources of drugs of abuse magic mushrooms In Cole SM ed New Research on Street Drugs New York New York Nova Science Publishers pp 167 186 ISBN 978 1 59454 961 8 Archived from the original on April 4 2017 Retrieved February 27 2016 a b Studerus E Kometer M Hasler F Vollenweider FX 2011 Acute subacute and long term subjective effects of psilocybin in healthy humans a pooled analysis of experimental studies Journal of Psychopharmacology 25 11 1434 1452 doi 10 1177 0269881110382466 PMID 20855349 S2CID 22923427 a b MacLean KA Johnson MW Griffiths RR 2011 Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness Journal of Psychopharmacology 25 11 1453 1461 doi 10 1177 0269881111420188 PMC 3537171 PMID 21956378 Griffiths RR Johnson MW Richards WA Richards BD Jesse R MacLean KA et al January 2018 Psilocybin occasioned mystical type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors Journal of Psychopharmacology 32 1 49 69 doi 10 1177 0269881117731279 PMC 5772431 PMID 29020861 Psilocybin from magic mushrooms plus meditation and spiritual training leads to lasting changes in positive traits January 19 2018 Archived from the original on February 21 2019 Retrieved February 21 2019 Frecska E Luna LE 2006 The adverse effects of hallucinogens from intramural perspective PDF Neuropsychopharmacologia Hungarica 8 4 189 200 PMID 17211054 Archived PDF from the original on September 16 2018 Retrieved December 27 2011 Quentin AM 1960 La Psilocybine en Psychiatrie Clinique et Experimentale Psilocybin in Clinical and Experimental Psychiatry PhD thesis in French Paris France Paris University Medical Dissertation See for example Isbell H 1959 Comparison of the reactions induced by psilocybin and LSD 25 in man Psychopharmacologia 1 1 29 38 doi 10 1007 BF00408109 PMID 14405870 S2CID 19508675 Hollister LE Prusmack JJ Paulsen A Rosenquist N 1960 Comparison of three psychotropic drugs psilocybin JB 329 and IT 290 in volunteer subjects Journal of Nervous and Mental Disease 131 5 428 434 doi 10 1097 00005053 196011000 00007 PMID 13715375 S2CID 8255131 Malitz S Esecover H Wilkens B Hoch PH 1960 Some observations on psilocybin a new hallucinogen in volunteer subjects Comprehensive Psychiatry 1 8 17 doi 10 1016 S0010 440X 60 80045 4 PMID 14420328 permanent dead link Rinkel M Atwell CR Dimascio A Brown J 1960 Experimental psychiatry V Psilocybine a new psychotogenic drug New England Journal of Medicine 262 6 295 297 doi 10 1056 NEJM196002112620606 PMID 14437505 Parashos AJ 1976 The psilocybin induced state of drunkenness in normal volunteers and schizophrenics Behavioral Neuropsychiatry 8 1 12 83 86 PMID 1052267 Heimann H 1994 Experience of time and space in model psychoses In Pletscher A Ladewig D eds 50 Years of LSD Current Status and Perspectives of Hallucinogens New York New York The Parthenon Publishing Group pp 59 66 ISBN 978 1 85070 569 7 a b Wittmann M Carter O Hasler F Cahn BR Grimberg U Spring P Hell D Flohr H Vollenweider FX 2007 Effects of psilocybin on time perception and temporal control of behaviour in humans Journal of Psychopharmacology 21 1 50 64 doi 10 1177 0269881106065859 PMID 16714323 S2CID 3165579 Wackermann J Wittmann M Hasler F Vollenweider FX 2008 Effects of varied doses of psilocybin on time interval reproduction in human subjects Neuroscience Letters 435 1 51 55 doi 10 1016 j neulet 2008 02 006 PMID 18325673 S2CID 22789140 Carter OL Burr DC Pettigrew JD Wallis GM Hasler F Vollenweider FX 2005 Using psilocybin to investigate the relationship between attention working memory and the serotonin 1A and 2A receptors PDF Journal of Cognitive Neuroscience 17 10 1497 1508 doi 10 1162 089892905774597191 PMID 16269092 S2CID 9790150 Archived PDF from the original on August 16 2019 Retrieved August 16 2019 Harrington DL Haaland KY 1999 Neural underpinnings of temporal processing a review of focal lesion pharmacological and functional imaging research Reviews in the Neurosciences 10 2 91 116 doi 10 1515 REVNEURO 1999 10 2 91 PMID 10658954 S2CID 25960626 a b Coull JT Cheng RK Meck WH 2011 Neuroanatomical and neurochemical substrates of timing Neuropsychopharmacology 36 1 3 25 doi 10 1038 npp 2010 113 PMC 3055517 PMID 20668434 a b Attema de Jonge ME Portier CB Franssen EJ 2007 Automutilatie na gebruik van hallucinogene paddenstoelen Automutilation after consumption of hallucinogenic mushrooms Nederlands Tijdschrift voor Geneeskunde in Dutch 151 52 2869 2872 PMID 18257429 a b c Stafford PJ 1992 Psychedelics Encyclopedia 3rd ed Berkeley California Ronin Publishing ISBN 978 0 914171 51 5 Drug Addictions Hallucinogens and Shamanism the View from Anthropology Document Gale Academic OneFile Archived from the original on August 23 2021 Retrieved August 23 2021 a b c d Batchelder T 2001 Drug Addictions Hallucinogens and Shamanism the View from Anthropology Drug Addictions Hallucinogens and Shamanism Townsend Letter for Doctors and Patients 217 74 77 Archived from the original on October 19 2021 Retrieved August 23 2021 via Gale Academic OneFile Leary T 2007 The psychedelic experience a manual based on the Tibetan book of the dead Ralph Metzner Ram Dass activeth century Karma gliṅ pa New York Citadel Press ISBN 978 0 8065 1652 3 OCLC 318713242 Archived from the original on October 19 2021 Retrieved August 23 2021 Hendricks PS October 2020 Psilocybin assisted group therapy A new hope for demoralization eClinicalMedicine 27 100557 doi 10 1016 j eclinm 2020 100557 PMC 7549063 PMID 33073220 Winkelman MJ 2007 Therapeutic bases of psychedelic medicines psychointegrative effects In Winkelman MJ Roberts TB eds Psychedelic Medicine New Evidence for Hallucinogenic Substances as Treatments Vol 1 Westport Connecticut Praeger pp 1 19 ISBN 978 0 275 99024 4 McKenna T 1993 Food of the Gods The Search for the Original Tree of Knowledge A Radical History of Plants Drugs and Human Evolution New York New York Bantam Books ISBN 978 0 553 37130 7 James W 1902 The Varieties of Religious Experience New York New York Simon amp Schuster ISBN 978 0 684 84297 4 Metzner R 1998 Hallucinogenic drugs and plants in psychotherapy and shamanism PDF Journal of Psychoactive Drugs 30 4 333 341 CiteSeerX 10 1 1 509 4769 doi 10 1080 02791072 1998 10399709 PMID 9924839 Archived PDF from the original on September 21 2017 Retrieved October 26 2017 Pahnke WN Richards W 1966 Implications of LSD and experimental mysticism Journal of Religion and Health 5 3 175 208 doi 10 1007 BF01532646 PMID 24424798 S2CID 18464414 Pahnke WN 1966 Drugs and mysticism International Journal of Parapsychology 8 2 295 315 a b Griffiths R Richards W Johnson M McCann U Jesse R 2008 Mystical type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later PDF Journal of Psychopharmacology 22 6 621 632 doi 10 1177 0269881108094300 PMC 3050654 PMID 18593735 Archived from the original PDF on July 22 2008 Retrieved July 3 2008 Smith H 2000 Cleansing the Doors of Perception The Religious Significance of Entheogenic Plants and Chemicals New York New York Jeremy P Tarcher Putnam p 101 ISBN 978 1 58542 034 6 a b Doblin R 1991 Pahnke s Good Friday Experiment a long term follow up and methodological critique Journal of Transpersonal Psychology 23 1 1 25 Richards WA 2008 The phenomenology and potential religious import of states of consciousness facilitated by psilocybin Archive for the Psychology of Religion 30 1 189 199 doi 10 1163 157361208X317196 S2CID 144969540 Griffiths RR Richards WA McCann U Jesse R 2006 Psilocybin can occasion mystical type experiences having substantial and sustained personal meaning and spiritual significance PDF Psychopharmacology 187 3 268 283 doi 10 1007 s00213 006 0457 5 PMID 16826400 S2CID 7845214 Archived from the original PDF on November 9 2011 Press release Griffiths psilocybin Johns Hopkins Medicine July 11 2006 Archived from the original on July 16 2011 Retrieved July 12 2006 Hood Jr RW 1975 The construction and preliminary validation of a measure of reported mystical experience Journal for the Scientific Study of Religion 14 1 29 41 doi 10 2307 1384454 JSTOR 1384454 S2CID 147200008 Smith M July 12 2006 Medical News Psilocybin Viewed as Therapy or Research Tool Medpagetoday com Archived from the original on October 5 2008 Retrieved February 12 2011 a b Carhart Harris R Nutt D 2010 User perceptions of the benefits and harms of hallucinogenic drug use a web based questionnaire study Journal of Substance Abuse 15 4 283 300 doi 10 3109 14659890903271624 S2CID 56427651 Paul McHugh reviews Don Lattin s The Harvard Psychedelic Club commentarymagazine com April 1 2010 Archived from the original on April 10 2019 Retrieved April 10 2019 a b Hillebrand J Olszewski D Sedefov R 2006 Hallucinogenic Mushrooms An Emerging Trend Case Study PDF Report Lisbon Portugal European Monitoring Centre for Drugs and Drug Addiction EMCDDA ISBN 92 9168 249 7 Archived PDF from the original on March 29 2012 Retrieved September 8 2011 Pagliaro LA Pagliaro AM 2012 Handbook of Child and Adolescent Drug and Substance Abuse Pharmacological Developmental and Clinical Considerations 2nd ed Hoboken New Jersey John Wiley amp Sons p 199 ISBN 978 0 470 63906 1 Archived from the original on April 3 2017 Retrieved February 27 2016 Schaefer C 2001 Drugs During Pregnancy and Lactation Handbook of Prescription Drugs and Comparative Risk Assessment Amsterdam the Netherlands Elsevier p 222 ISBN 978 0 444 50763 1 Archived from the original on April 3 2017 Retrieved February 27 2016 a b Reinert JP Colunga K Etuk A Richardson V Dunn RL August 2020 Management of overdoses of salvia kratom and psilocybin mushrooms a literature review Expert Rev Clin Pharmacol Review 13 8 847 856 doi 10 1080 17512433 2020 1794811 PMID 32648791 S2CID 220472473 a b O Neil MJ Smith A Heckelman PE Obenchain JR Gallipeau JR D Arecca MA eds 2001 The Merck Index An Encyclopedia of Chemicals Drugs and Biologicals 13th ed Whitehouse Station New Jersey Merck p 1419 ISBN 978 0 911910 13 1 Gable RS 2004 Comparison of acute lethal toxicity of commonly abused psychoactive substances PDF Addiction 99 6 686 696 doi 10 1111 j 1360 0443 2004 00744 x PMID 15139867 Archived PDF from the original on August 10 2006 Retrieved November 16 2011 Strassman R Wojtowicz S Luna LE Frecska E 2008 Inner Paths to Outer Space Journeys to Alien Worlds through Psychedelics and Other Spiritual Technologies Rochester Vermont Park Street Press p 147 ISBN 978 1 59477 224 5 Archived from the original on April 4 2017 Retrieved February 27 2016 Gerault A Picart D 1996 Intoxication mortelle a la suite de la consommation volontaire et en groupe de champignons hallucinogenes Fatal poisoning after a group of people voluntarily consumed hallucinogenic mushrooms Bulletin de la Societe Mycologique de France in French 112 1 14 Gartz J Samorini G Festi F 1996 On the presumed French case of fatality caused by ingestion of Liberty Caps Eluesis 6 40 41 Archived from the original on April 5 2012 Peden NR Pringle SD Crooks J 1982 The problem of psilocybin mushroom abuse Human Toxicology 1 4 417 424 doi 10 1177 096032718200100408 PMID 7173927 S2CID 7453965 a b Vollenweider FX Vollenweider Scherpenhuyzen MF Babler A Vogel H Hell D 1998 Psilocybin induces schizophrenia like psychosis in humans via a serotonin 2 agonist action PDF NeuroReport 9 17 3897 3902 doi 10 1097 00001756 199812010 00024 PMID 9875725 S2CID 37706068 Archived from the original PDF on March 3 2019 Hyde C Glancy P Omerod P Hall D Taylor GS 1978 Abuse of indigenous psilocybin mushrooms a new fashion and some psychiatric complications British Journal of Psychiatry 132 6 602 604 doi 10 1192 bjp 132 6 602 PMID 566144 S2CID 20020560 Mack RB 1983 Phenomenally phunny phungi psilocybin toxicity New Castle Medical Journal 44 10 639 640 PMID 6580536 Simeon D 2004 Depersonalisation disorder a contemporary overview CNS Drugs 18 6 343 354 doi 10 2165 00023210 200418060 00002 PMID 15089102 S2CID 18506672 Nielen RJ van der Heijden FM Tuinier S Verhoeven WM January 2004 Khat and mushrooms associated with psychosis The World Journal of Biological Psychiatry 5 1 49 53 doi 10 1080 15622970410029908 PMID 15048636 S2CID 44321700 Geyer MA 1998 Behavioral studies of hallucinogenic drugs in animals implications for schizophrenia research Pharmacopsychiatry 31 S2 73 79 doi 10 1055 s 2007 979350 PMID 9754837 a b Vollenweider FX Geyer MA 2001 A systems model of altered consciousness integrating natural and drug induced psychoses Brain Research Bulletin 56 5 495 507 doi 10 1016 S0361 9230 01 00646 3 PMID 11750795 S2CID 230298 Geyer MA Vollenweider FX 2008 Serotonin research contributions to understanding psychoses Trends in Pharmacological Sciences 29 9 445 453 doi 10 1016 j tips 2008 06 006 PMID 19086254 Myers LS Watkins SS Carter TJ 1998 Flashbacks in theory and practice PDF The Heffter Review of Psychedelic Research 1 51 57 Archived PDF from the original on September 27 2011 Retrieved August 14 2011 Gable RS 2006 Acute toxicity of drugs versus regulatory status In Fish JM ed Drugs and Society U S Public Policy Lanham Maryland Rowman amp Littlefield pp 149 162 Table 7 1 Safety Ratio and Dependence Potential of Psychoactive Drugs ISBN 978 0 7425 4245 7 Archived from the original on January 7 2012 Nicholas LG Ogame K 2006 Psilocybin Mushroom Handbook Easy Indoor and Outdoor Cultivation Oakland California Quick American Archives p 164 ISBN 978 0 932551 71 9 Archived from the original on April 4 2017 Retrieved February 27 2016 Passie T Halpern JH Stichtenoth Emrich HM Hintzen A 2008 The pharmacology of lysergic acid diethyamide a review CNS Neuroscience amp Therapeutics 14 4 295 314 doi 10 1111 j 1755 5949 2008 00059 x PMC 6494066 PMID 19040555 a b Halberstadt AL Geyer MA 2011 Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens Neuropharmacology 61 3 364 381 doi 10 1016 j neuropharm 2011 01 017 PMC 3110631 PMID 21256140 Chen CY Storr CL Anthony JC 2008 Early onset drug use and risk for drug dependence problems Addictive Behaviors 34 3 319 322 doi 10 1016 j addbeh 2008 10 021 PMC 2677076 PMID 19022584 van Amsterdam J Opperhuizen A Koeter M van den Brink W 2010 Ranking the harm of alcohol tobacco and illicit drugs for the individual and the population European Addiction Research 16 4 202 207 doi 10 1159 000317249 PMID 20606445 S2CID 207669364 Nutt DJ King LA Phillips LD 2010 Drug harms in the UK a multicriteria decision analysis Lancet 376 9752 1558 1565 CiteSeerX 10 1 1 690 1283 doi 10 1016 S0140 6736 10 61462 6 PMID 21036393 S2CID 5667719 Azmitia EC 2010 Evolution of serotonin sunlight to suicide In Muller CP Jacobs BL eds Handbook of the Behavioral Neurobiology of Serotonin London UK Academic Press p 7 ISBN 978 0 12 374634 4 Archived from the original on April 4 2017 Retrieved February 27 2016 a b c d Wurst M Kysilka R Flieger M 2002 Psychoactive tryptamines from Basidiomycetes Folia Microbiologica 47 1 3 27 doi 10 1007 BF02818560 PMID 11980266 S2CID 31056807 a b Psilocybine Hazardous Substances Data Bank U S National Library of Medicine Archived from the original on August 13 2018 Retrieved November 21 2011 Sherwood A M Kargbo R B Kaylo K W Cozzi N V Meisenheimer P Kaduk J A January 1 2022 Psilocybin crystal structure solutions enable phase analysis of prior art and recently patented examples Acta Crystallographica Section C Structural Chemistry 78 1 36 55 doi 10 1107 S2053229621013164 ISSN 2053 2296 PMC 8725723 PMID 34982048 a b Anastos N Barnett NW Pfeffer FM 2006 Investigation into the temporal stability of aqueous standard solutions of psilocin and psilocybin using high performance liquid chromatography Science amp Justice 46 2 91 96 doi 10 1016 S1355 0306 06 71579 9 PMID 17002211 a b Serreau Raphael Amirouche Ammar Benyamina Amine Berteina Raboin Sabine 2023 A Review of Synthetic Access to Therapeutic Compounds Extracted from Psilocybe Pharmaceuticals Basel 16 1 40 doi 10 3390 ph16010040 PMC 9867295 PMID 36678537 a b c Fricke J Blei F Hoffmeister D September 2017 Enzymatic synthesis of psilocybin Angewandte Chemie 56 40 12352 12355 doi 10 1002 anie 201705489 PMID 28763571 Agurell S Nilsson JL 1968 Biosynthesis of psilocybin Part II Incorporation of labelled tryptamine derivatives Acta Chemica Scandinavica 22 4 1210 1218 doi 10 3891 acta chem scand 22 1210 PMID 5750023 a b Reynolds HT Vijayakumar V Gluck Thaler E Korotkin HB Matheny PB Slot JC April 2018 Horizontal gene cluster transfer increased hallucinogenic mushroom diversity Evolution Letters 2 2 88 101 doi 10 1002 evl3 42 PMC 6121855 PMID 30283667 Satyanarayana M October 7 2019 Modified E coli pump out psilocybin Chemical amp Engineering News 97 39 11 doi 10 1021 cen 09739 scicon9 S2CID 208747979 Archived from the original on December 3 2019 Retrieved December 3 2019 Milne N Thomsen P Knudsen N Rubaszka P Kristensen M Borodina I 2020 Metabolic engineering of Saccharomyces cerevisiae for the de novo production of psilocybin and related tryptamine derivatives Metabolic Engineering 60 25 36 doi 10 1016 j ymben 2019 12 007 PMC 7232020 PMID 32224264 Wong Garrett Lim Li Rong Tan Yong Quan Go Maybelle Kho Bell David J Freemont Paul S Yew Wen Shan 2022 Reconstituting the complete biosynthesis of D lysergic acid in yeast Nature Communications 13 1 712 Bibcode 2022NatCo 13 712W doi 10 1038 s41467 022 28386 6 PMC 8821704 PMID 35132076 a b Vargas MV Meyer R Avanes AA Rus M Olson DE 2021 Psychedelics and Other Psychoplastogens for Treating Mental Illness Frontiers in Psychiatry 12 727117 doi 10 3389 fpsyt 2021 727117 PMC 8520991 PMID 34671279 a b Olson David E September 19 2018 Psychoplastogens A Promising Class of Plasticity Promoting Neurotherapeutics Journal of Experimental Neuroscience 12 1179069518800508 doi 10 1177 1179069518800508 ISSN 1179 0695 PMC 6149016 PMID 30262987 a b de Vos Cato M H Mason Natasha L Kuypers Kim P C 2021 Psychedelics and Neuroplasticity A Systematic Review Unraveling the Biological Underpinnings of Psychedelics Frontiers in Psychiatry 12 1575 doi 10 3389 fpsyt 2021 724606 ISSN 1664 0640 PMC 8461007 PMID 34566723 Karch SB 2007 Pharmacokinetics and Pharmacodynamics of Abused Drugs Boca Raton Florida CRC Press p 148 ISBN 978 1 4200 5458 3 Archived from the original on April 4 2017 Retrieved February 27 2016 PDSP Ki Database PDSP Archived from the original on May 9 2021 Retrieved January 20 2020 Adams Jr JD 2009 Chemical interactions with pyramidal neurons in layer 5 of the cerebral cortex control of pain and anxiety Current Medicinal Chemistry 16 27 3476 3279 doi 10 2174 092986709789057626 PMID 19799545 Mason NL Kuypers KP Muller F Reckweg J Tse DH Toennes SW et al November 2020 Me myself bye regional alterations in glutamate and the experience of ego dissolution with psilocybin Neuropsychopharmacology 45 12 2003 2011 doi 10 1038 s41386 020 0718 8 PMC 7547711 PMID 32446245 a b c d e f g Stamets P 1996 Psilocybin Mushrooms of the World An Identification Guide Berkeley California Ten Speed Press ISBN 978 0 89815 839 7 a b Grieshaber AF Moore KA Levine B 2001 The detection of psilocin in human urine Journal of Forensic Sciences 46 3 627 630 doi 10 1520 JFS15014J PMID 11373000 Hasler F Bourquin D Brenneisen R Vollenweider FX 2002 Renal excretion profiles of psilocin following oral administration of psilocybin a controlled study in man Journal of Pharmaceutical and Biomedical Analysis 30 2 331 339 doi 10 1016 S0731 7085 02 00278 9 PMID 12191719 Meyer MR Maurer HH 2011 Absorption distribution metabolism and excretion pharmacogenomics of drugs of abuse Pharmacogenomics 12 2 215 233 doi 10 2217 pgs 10 171 PMID 21332315 a b Matsushima Y Eguchi F Kikukawa T Matsuda T 2009 Historical overview of psychoactive mushrooms Inflammation and Regeneration 29 1 47 58 doi 10 2492 inflammregen 29 47 Baselt RC 2008 Disposition of Toxic Drugs and Chemicals in Man 8th ed Foster City California Biomedical Publications pp 1346 1348 ISBN 978 0 9626523 7 0 Beck O Helander A Karlson Stiber C Stephansson N 1998 Presence of phenylethylamine in hallucinogenic Psilocybe mushroom possible role in adverse reactions Journal of Analytical Toxicology 22 1 45 49 doi 10 1093 jat 22 1 45 PMID 9491968 van Amsterdam J Talhout R Vleeming W Opperhuizen A 2006 Contribution of monoamine oxidase MAO inhibition to tobacco and alcohol addiction Life Sciences 79 21 1969 1973 doi 10 1016 j lfs 2006 06 010 PMID 16884739 Jenkins AJ 2003 Hallucinogens In Levine B ed Principles of Forensic Toxicology 2nd ed Washington D C American Association for Clinical Chemistry Press p 281 ISBN 978 1 890883 87 4 Archived from the original on April 3 2017 Retrieved February 27 2016 Cole MD 2003 The Analysis of Controlled Substances New York Chichester John Wiley and Sons pp 132 133 ISBN 978 0 471 49252 8 Bresinsky A Besl H 1989 A Colour Atlas of Poisonous Fungi A Handbook for Pharmacists Doctors and Biologists London UK Manson Publishing p 113 ISBN 978 0 7234 1576 3 Archived from the original on April 4 2017 Retrieved February 27 2016 Kamata T Katagi M Tsuchihashi H 2010 Metabolism and toxicological analyses of hallucinogenic tryptamine analogues being abused in Japan Forensic Toxicology 28 1 1 8 doi 10 1007 s11419 009 0087 9 S2CID 45118221 a b Keller T Schneider A Regenscheit P Dirnhofer R Rucker T Jaspers J Kisser W 1999 Analysis of psilocybin and psilocin in Psilocybe subcubensis Guzman by ion mobility spectrometry and gas chromatography mass spectrometry Forensic Science International 99 2 93 105 doi 10 1016 S0379 0738 98 00168 6 PMID 10077856 Pedersen Bjergaard S Sannes E Rasmussen K Tonneson F 1997 Determination of psilocybin in Psilocybe semilanceata by capillary zone electrophoresis Journal of Chromatography 694 2 375 381 doi 10 1016 S0378 4347 97 00127 8 PMID 9252052 Lee RE 1985 A technique for the rapid isolation and identification of psilocin from psilocin psilocybin containing mushrooms Journal of Forensic Sciences 30 3 931 941 doi 10 1520 JFS11028J PMID 4040953 Wurst M Kysilka R Koza T 1992 Analysis and isolation of indole alkaloids of fungi by high performance liquid chromatography Journal of Chromatography 593 1 2 201 208 doi 10 1016 0021 9673 92 80287 5 Saito K Toyo oka T Fukushima T Kato M Shirota O Goda Y 2004 Determination of psilocin in magic mushrooms and rat plasma by liquid chromatography with fluorimetry and electrospray ionization mass spectrometry Analytica Chimica Acta 527 2 149 156 doi 10 1016 j aca 2004 08 071 a b Lindenblatt H Kramer E Holzmann Erens P Gouzoulis Mayfrank E Kovar K 1998 Quantitation of psilocin in human plasma by high performance liquid chromatography and electrochemical detection comparison of liquid liquid extraction with automated on line solid phase extraction Journal of Chromatography 709 2 255 263 doi 10 1016 S0378 4347 98 00067 X PMID 9657222 Rodriguez Cruz SE 2005 Analysis and characterization of psilocybin and psilocin using liquid chromatography electrospray ionization mass spectrometry LC ESI MS with collision induced dissociation CID and source induced dissociation SID Microgram Journal 3 3 4 175 82 Archived from the original on April 29 2011 a b Sticht G Kaferstein H 2000 Detection of psilocin in body fluids Forensic Science International 113 1 403 407 doi 10 1016 S0379 0738 00 00213 9 PMID 10978655 Kysilka R 1990 Determination of psilocin in rat urine by high performance liquid chromatography with electrochemical detection Journal of Chromatography 534 287 290 doi 10 1016 S0378 4347 00 82176 3 PMID 2094720 Kamata T Nishikawa M Katagi M Tsuchihashi H 2003 Optimized glucuronide hydrolysis for the detection of psilocin in human urine samples Journal of Chromatography B 792 2 421 427 doi 10 1016 j jchromb 2003 08 030 PMID 14581081 Albers C Kohler H Lehr M Brinkmann B Beike J 2004 Development of a psilocin immunoassay for serum and blood samples International Journal of Legal Medicine 118 6 326 331 doi 10 1007 s00414 004 0469 9 PMID 15526212 S2CID 11249439 Lurie I Li L 2009 Use of high temperature liquid chromatography with sub 2 mm particle C18 columns for the analysis of seized drugs Journal of Liquid Chromatography amp Related Technologies 32 17 20 2615 2626 doi 10 1080 10826070903245516 S2CID 96753191 Archived from the original on May 3 2021 Retrieved August 24 2020 a b Guzman G Allen JW Gartz J 2000 A worldwide geographical distribution of the neurotropic fungi an analysis and discussion PDF Annali del Museo Civico di Rovereto Sezione Archeologia Storia Scienze Naturali 14 189 280 Archived PDF from the original on February 5 2018 Retrieved October 19 2021 a b Guzman G 2005 Species diversity of the genus Psilocybe Basidiomycotina Agaricales Strophariaceae in the world mycobiota with special attention to hallucinogenic properties International Journal of Medicinal Mushrooms 7 1 2 305 331 doi 10 1615 intjmedmushr v7 i12 280 Yong E August 24 2017 How Mushrooms Became Magic The Atlantic Archived from the original on March 16 2018 Retrieved March 15 2018 Guzman G 1983 The GenusPsilocybe A Systematic Revision of the Known Species Including the History Distribution and Chemistry of the Hallucinogenic Species Beihefte Zur Nova Hedwigia Heft 74 Vaduz Liechtenstein J Cramer pp 361 362 ISBN 978 3 7682 5474 8 Saupe SG 1981 Occurrence of psilocybin psilocin in Pluteus salicinus Plutaceae Mycologia 73 4 871 874 doi 10 2307 3759505 JSTOR 3759505 Archived from the original on March 10 2017 Retrieved August 29 2011 Guzman G Allen JW Gartz J 1998 A worldwide geographical distribution of the neurotropic fungi an analysis and discussion PDF Annali del Museo Civico di Rovereto 14 207 Archived from the original PDF on June 26 2010 Retrieved September 17 2017 Wurst M Semerdzieva M Vokoun J 1984 Analysis of psychotropic compounds in fungi of the genus Psilocybe by reversed phase high performance liquid chromatography Journal of Chromatography A 286 229 235 doi 10 1016 S0021 9673 01 99190 3 Kysilka R Wurst M 1989 High performance liquid chromatographic determination of some psychotropic indole derivatives Journal of Chromatography 464 2 434 437 doi 10 1016 s0021 9673 00 94264 x PMID 2722990 a b Bigwood J Beug MW 1982 Variation of psilocybin and psilocin levels with repeated flushes harvests of mature sporocarps of Psilocybe cubensis Earle Singer Journal of Ethnopharmacology 5 3 287 291 doi 10 1016 0378 8741 82 90014 9 PMID 7201054 Gartz J 1992 New aspects of the occurrence chemistry and cultivation of European hallucinogenic mushrooms Supplemento Agli Annali dei Musei Civici di Rovereto Sezione Archeologica Storia e Scienze Naturali 8 107 124 Laussmann Tim Meier Giebing Sigrid February 25 2010 Forensic analysis of hallucinogenic mushrooms and khat Catha edulis Forsk using cation exchange liquid chromatography Forensic Science International 195 1 3 160 164 doi 10 1016 j forsciint 2009 12 013 ISSN 1872 6283 PMID 20047807 Drug profiles Hallucinogenic mushrooms European Monitoring Centre for Drugs and Drug Addiction September 19 2011 Archived from the original on November 27 2011 Retrieved December 4 2011 Ohenoja E Jokiranta J Makinen T Kaikkonen A Airaksinen MM 1987 The occurrence of psilocybin and psilocin in Finnish fungi Journal of Natural Products 50 4 741 744 doi 10 1021 np50052a030 PMID 3430170 Gross ST 2000 Detecting psychoactive drugs in the developmental stages of mushrooms PDF Journal of Forensic Sciences 45 3 527 537 doi 10 1520 JFS14725J PMID 10855955 S2CID 38006957 Archived from the original PDF on November 16 2020 Akers BP Ruiz JF Piper A Ruck CA 2011 A prehistoric mural in Spain depicting neurotropic Psilocybe mushrooms Economic Botany 65 2 121 128 doi 10 1007 s12231 011 9152 5 S2CID 3955222 Samorini Giorgio 1992 The oldest representations of hallucinogenic mushrooms in the world Sahara Desert 9000 7000 BP Integration Zeitschrift fur geistbewegende Pflanzen und Kultur 2 3 69 65 permanent dead link a b c d Marley G 2010 Chanterelle Dreams Amanita Nightmares The Love Lore and Mystique of Mushrooms White River Junction Vermont Chelsea Green Publishing ISBN 978 1603582148 a b c d Hofmann A 2009 LSD my problem child reflections on sacred drugs mysticism and science Santa Cruz California Multidisciplinary Association for Psychedelic Studies ISBN 978 0979862229 Nyberg H 1992 Religious use of hallucinogenic fungi A comparison between Siberian and Mesoamerican Cultures Karstenia 32 2 71 80 doi 10 29203 ka 1992 294 Wasson RG 1968 Soma Divine Mushroom of Immortality Harcourt Brace Jovanovick p 161 ISBN 978 0 88316 517 1 a b Gartz J 1997 Magic Mushrooms Around the World Los Angeles California LIS Publications ISBN 978 0 9653399 0 2 Wasson RG May 13 1957 Seeking the magic mushroom Life pp 101 120 ISSN 0024 3019 Archived from the original on April 3 2017 Retrieved February 27 2016 Heim R 1957 Notes preliminaires sur les agarics hallucinogenes du Mexique Preliminary notes on the hallucination producing agarics of Mexico Revue de Mycologie in French 22 1 58 79 Leary T Metzner R Presnell M Weil G Schwitzgebel R Kinne S 1965 A new behavior change program using psilocybin Psychotherapy Theory Research amp Practice 2 2 61 72 doi 10 1037 h0088612 Johnson MW Richards WA Griffiths RR 2008 Human hallucinogen research guidelines for safety PDF Journal of Psychopharmacology 22 6 603 620 doi 10 1177 0269881108093587 PMC 3056407 PMID 18593734 Archived from the original PDF on November 20 2017 Retrieved November 20 2017 The War on Drugs turns 50 today It s time to make peace The Washington Post Retrieved August 8 2023 Griffiths RR Grob CS 2010 Hallucinogens as medicine PDF Scientific American 303 6 77 79 Bibcode 2010SciAm 303f 76G doi 10 1038 scientificamerican1210 76 Archived from the original PDF on October 3 2011 Retrieved July 25 2011 a b Ott J 1993 Pharmacotheon Entheogenic Drugs their Plant Sources and History Kennewick Washington Natural Products Company ISBN 978 0 9614234 3 8 Oeric OT Os ON 1991 Psilocybin Magic Mushroom Grower s Guide 2nd ed San Francisco California Quick American Archives ISBN 978 0 932551 06 1 San Antonio JP 1971 A laboratory method to obtain fruit from cased grain spawn of the cultivated mushroom Agaricus bisporus Mycologia 63 1 16 21 doi 10 2307 3757680 JSTOR 3757680 PMID 5102274 Archived from the original on September 23 2015 Retrieved September 7 2011 Keim B July 1 2008 Psilocybin study hints at rebirth of hallucinogen research Wired com Archived from the original on August 3 2011 Retrieved August 8 2011 Miller G July 1 2008 A very memorable trip sciencemag org Archived from the original on August 13 2018 Retrieved August 8 2011 List of psychotropic substances under international control PDF International Narcotics Control Board August 2003 Archived from the original PDF on December 5 2005 Retrieved June 25 2007 Griffiths amp Grob Roland R amp Charles S Hallucinogens as Medicine PDF Scientific American Archived from the original PDF on October 3 2011 Retrieved March 22 2013 Szalavitz Maia June 16 2011 Magic Mushrooms Can Improve Psychological Health Long Term Time Retrieved March 22 2013 Griffiths Roland R 2011 Psilocybin occasioned mystical type experiences immediate and persisting dose related effects Psychopharmacology 218 4 649 665 doi 10 1007 s00213 011 2358 5 PMC 3308357 PMID 21674151 Jerome Lisa Psilocybin Investigator s Brochure PDF MAPS Archived from the original PDF on March 19 2013 Retrieved March 22 2013 Schaepe Herbert September 13 2001 UN s INCB Psilocybin Mushroom Policy Erowid org Retrieved January 7 2012 As you are aware mushrooms containing the above substances are collected and used for their hallucinogenic effects As a matter of international law no plants natural material containing psilocin and psilocybin are at present controlled under the Convention on Psychotropic Substances of 1971 Consequently preparations made of these plants are not under international control and therefore not subject of the articles of the 1971 Convention emphasis added Criminal cases are decided with reference to domestic law which may otherwise provide for controls over mushrooms containing psilocine and psilocybin As the Board can only speak as to the contours of the international drug conventions I am unable to provide an opinion on the litigation in question Letter from Secretary of the UN International Narcotics Control Board to the Dutch Ministry of Health Hardon A van Schipstal I Berning M Mishra S Murray H Mandler T Kamps D Hymans TD December 2020 Caring for Hassle Free Highs in Amsterdam Anthropology and Humanism 45 2 212 22 doi 10 1111 anhu 12298 S2CID 228997721 a b Pollan M 2018 Como mudar sua mente How to kill your mind in Portuguese Editora Intrinseca ISBN 9788551004173 Shipley M November 2015 Psychedelic mysticism Transforming consciousness religious experiences and voluntary peasants in postwar America Lexington Books ISBN 978 1 4985 0910 7 Lu Donna writer Donna Lu Science June 30 2023 Australian psychiatrists can now prescribe MDMA and psilocybin who can access them and how do they work The Guardian ISSN 0261 3077 Retrieved July 18 2023 Submission to the Western Australian Inquiry Into Alternative Approaches to Reducing Illicit Drug Use and Its Effects on the Community PDF Report Australian Psychedelic Society Inc January 30 2019 Archived PDF from the original on August 23 2021 Retrieved August 23 2021 Johansen PO Krebs TS March 2015 Psychedelics not linked to mental health problems or suicidal behavior a population study Journal of Psychopharmacology 29 3 270 9 doi 10 1177 0269881114568039 PMID 25744618 S2CID 2025731 Johnson MW Griffiths RR Hendricks PS Henningfield JE November 2018 The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act Neuropharmacology 142 143 166 doi 10 1016 j neuropharm 2018 05 012 PMC 6791528 PMID 29753748 Rodd R September 2018 It s all you Australian ayahuasca drinking spiritual development and immunitary individualism Critique of Anthropology 38 3 325 45 doi 10 1177 0308275X18775818 S2CID 149858755 Bone E 2011 Mycophilia Revelations from the Weird World of Mushrooms New York New York Rodale pp 257 258 ISBN 978 1 60529 407 0 Archived from the original on April 4 2017 Retrieved February 27 2016 European Monitoring Centre for Drugs and Drug Addiction November 2011 Annual report 2011 the state of the drugs problem in Europe PDF Report Luxembourg Publications Office of the European Union doi 10 2810 44330 ISBN 978 92 9168 470 0 Archived PDF from the original on December 3 2011 Retrieved December 4 2011 Guzman G 2008 Hallucinogenic mushrooms in Mexico an overview Economic Botany 62 3 404 412 doi 10 1007 s12231 008 9033 8 S2CID 22085876 Wark C Galliher JF 2009 Timothy Leary Richard Alpert Ram Dass and the changing definition of psilocybin The International Journal on Drug Policy 21 3 234 239 doi 10 1016 j drugpo 2009 08 004 PMID 19744846 Goel Dev B Zilate Sarju 2022 Potential Therapeutic Effects of Psilocybin A Systematic Review Cureus 14 10 e30214 doi 10 7759 cureus 30214 PMC 9650681 PMID 36381758 Dos Santos RG Osorio FL Crippa JA Riba J Zuardi AW Hallak JE June 2016 Antidepressive anxiolytic and antiaddictive effects of ayahuasca psilocybin and lysergic acid diethylamide LSD a systematic review of clinical trials published in the last 25 years Therapeutic Advances in Psychopharmacology 6 3 193 213 doi 10 1177 2045125316638008 PMC 4910400 PMID 27354908 Ross S Bossis A Guss J Agin Liebes G Malone T Cohen B et al December 2016 Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life threatening cancer a randomized controlled trial Journal of Psychopharmacology 30 12 1165 1180 doi 10 1177 0269881116675512 PMC 5367551 PMID 27909164 COMPASS Pathways Receives FDA Breakthrough Therapy Designation for Psilocybin Therapy for Treatment resistant Depression Compass Pathways Archived from the original on December 4 2018 Retrieved December 3 2018 Richard Staines December 2 2019 FDA tags psilocybin drug as clinical depression Breakthrough Therapy Pharmaphorum Archived from the original on September 7 2021 Retrieved September 7 2021 Wieckiewicz G Stoklosa I Piegza M Gorczyca P Pudlo R August 2021 Lysergic Acid Diethylamide Psilocybin and Dimethyltryptamine in Depression Treatment A Systematic Review Pharmaceuticals 14 8 793 doi 10 3390 ph14080793 PMC 8399008 PMID 34451890 External links EditPsilocybin Investigator s Brochure Version 4 1 Usona Institute Madison Wisconsin 2021 Retrieved from https en wikipedia org w index php title Psilocybin amp oldid 1177150488, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.